%PDF-1.3
%
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
8 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2021-12-08T20:19:22-08:00
2021-10-14T18:03:03+05:30
application/pdf
LRB-2021-0056-ver9-Dai_3P 442..446
uuid:f54453c9-41a3-4570-a0a2-a73a9115a679
uuid:5554f1e7-bca2-40e8-a871-a3fe5c1eafe1
endstream
endobj
9 0 obj
<>stream
x+ |
endstream
endobj
10 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
11 0 obj
<>stream
x+ |
endstream
endobj
12 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
20 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 59.7543 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(treatment)-383.6(with)-379.9(prophylactic)-379.9(antibiotics)-383.5(is)-376.5(recognized)-384.4(as)-377.5(an)]TJ
0 -1.1174 TD
[(effective)-412.2(preventive)-406.4(approach.)]TJ
7.3823 0 0 6.5614 182.7779 718.5825 Tm
(2,3)Tj
9.843 0 0 9.843 195.9873 714.1605 Tm
[(The)-403.1(relationship)-407.5(between)]TJ
-13.8406 -1.1116 TD
[(cellulitis)-445.9(and)-436.4(lymphedema)-443.3(was)-437.1(conrmed)-438.4(by)-439.9(a)-434.2(secondary)]TJ
T*
[(analysis)-333.6(of)-336.2(the)-327.1(national)-334.1(database)-335.9(of)-330.5(the)-332.9(international)-335.2(epide-)]TJ
T*
[(miological)-804.2(study,)-798(that)-794.9(is,)-800.4(Lymphoedema)-796.8(IMpact)-799(and)]TJ
0 -1.1174 TD
[(PRevalenceINTernat)-16(ional)-277.6(\(LIMPRINT\).)]TJ
7.3823 0 0 6.5614 230.5133 674.7021 Tm
(7)Tj
9.843 0 0 9.843 69.7323 659.3951 Tm
[(Cellulitis)-411.2(in)-405.5(patients)-414.5(with)-408.7(lymphedema)-408.8(affects)-414.2(physical,)]TJ
-1.0137 -1.1116 TD
[(psychological,)-401.6(and)-401.9(social)-400.7(well-being.)-398.1(Developing)-406.1(cellulitis)]TJ
0 -1.1174 TD
[(may)-247.6(lead)-243(to)-244.2(worsening)-248(edema)-246.4(and)-240.6(risk)-246.2(of)-244.1(recurrent)-243.8(cellulitis.)]TJ
0 -1.1116 TD
[(Therefore,)-305.9(it)-302(affects)-299.1(not)-302.9(only)-298.3(the)-298.3(inammato)-9(ry)-295.9(cellulitis)-301.9(pe-)]TJ
T*
[(riod)-401.9(but)-395.1(also)-402.9(the)-396.3(long-term)-404.2(health)-400.9(status)-399.3(of)-399.6(these)-399.4(patients.)]TJ
0 -1.1174 TD
[(Prevention)-318.7(of)-318.9(cellulitis)-319.2(is)-313.2(an)-314.4(important)-317.9(clinical)-318.1(challenge)-320.1(in)]TJ
0 -1.1116 TD
[(lymphedema)-374.2(management)]TJ
7.3823 0 0 6.5614 164.9763 597.9967 Tm
(2)Tj
9.843 0 0 9.843 172.2897 593.6313 Tm
[(and)-367.3(requires)-368.1(a)-365.1(social)-371.9(approach.)]TJ
-11.433 -1.1116 TD
[(To)-233.8(prevent)-229(cellulitis,)-236.2(control)-228(of)-232.6(edema)-229.1(and)-229.1(early)-232.6(intervention)]TJ
T*
[(before)-187.4(the)-183.1(appearance)-190.8(of)-186.5(clinical)-185.6(symptoms)-183.8(are)-184.1(required.)]TJ
7.3823 0 0 6.5614 279.6094 576.1132 Tm
(8,9)Tj
9.843 0 0 9.843 290.6645 571.7479 Tm
(In)Tj
-23.4593 -1.1174 TD
[(lymphedema)-351.2(management,)-350(patients)-351.2(mainly)-343.3(follow)-347.5(self-care)]TJ
0 -1.1116 TD
[(at)-389.4(home.)]TJ
7.3823 0 0 6.5614 95.1307 554.1731 Tm
[(8,10)-8.6(,11)]TJ
9.843 0 0 9.843 121.096 549.8077 Tm
[(Therefore,)-392.3(it)-382.6(is)-388(important)-387(for)-383.4(patients)-391.5(to)-382.5(be)]TJ
-6.232 -1.1116 TD
[(educated)-301.6(regarding)-300.3(appropriate)-298(complex)-299.4(decongestive)-300.2(treat-)]TJ
0 -1.1174 TD
[(ment)-266.1(\(CDT\))-267.7(techniques,)-265.7(attend)-268.4(regular)-263.5(follow-ups,)-268.8(be)-262.5(aware)]TJ
0 -1.1116 TD
[(of)-244.1(the)-246.5(clinical)-243.2(signs)-247.2(of)-238.3(cellulitis)-250.1(to)-238.5(seek)-248.4(clinical)-243.2(care,)-247.4(and)-240.6(use)]TJ
T*
[(prescribed)-285.1(antibiotic)-284.7(treatment)-285.7(and/or)-284.3(care.)]TJ
7.3823 0 0 6.5614 230.9669 510.3495 Tm
(2,8)Tj
9.843 0 0 9.843 69.7323 494.9857 Tm
[(Health)-326.8(care)-330.4(services)-328.8(can)-328.2(only)-327.1(be)-325.9(improved)-328.1(with)-322.3(commu-)]TJ
-1.0137 -1.1116 TD
[(nication)-276.5(between)-277.1(patients)-276.3(and)-269.4(health)-274.1(care)-278.6(professionals.)-278.9(The)]TJ
T*
[(coronavirus)-457.8(disease-2019)-459.9(\(COVID-19\))-458(pandemic)-451.4(situation)]TJ
0 -1.1174 TD
[(has)-367.1(recently)-363.9(made)-359.3(telehealth)-367.5(systems)-366.8(attractive,)]TJ
7.3823 0 0 6.5614 253.0771 466.5258 Tm
(12)Tj
9.843 0 0 9.843 264.0755 462.1038 Tm
[(and)-361.6(they)]TJ
-20.758 -1.1116 TD
[(have)-283.2(been)-283.2(applied)-281(in)-278.8(many)-283.3(spheres)-286.1(of)-278.6(health)-279.9(care,)-282(including)]TJ
T*
[(lymphedema)-339.6(management.)-332.7(Telehealth)-339.8(refers)-331.2(to)-330.6(the)-332.9(practice)]TJ
T*
[(of)-244.1(caring)-239.4(for)-239.4(patients)-241.7(remotely)-243(when)-242.6(the)-240.7(health)-239.6(care)-244(provider)]TJ
0 -1.1174 TD
[(and)-580.4(patient)-586.4(are)-581.6(not)-579.4(physically)-578(present)-585.9(with)-581.5(each)-578.1(other.)]TJ
0 -1.1116 TD
[(Therefore,)-398.1(the)-396.3(effectiveness)-400.1(and)-390.4(wider)-399.3(applications)-397.2(of)-388.1(this)]TJ
T*
[(new)-281.8(approach)-288.7(must)-276.3(be)-285.6(evaluated.)]TJ
1.0137 -1.1174 TD
[(Ho)20(we)18.8(ve)13.9(r,)-315.5(th)20.7(e)-330.6(a)0(c)18.5(t)0(u)20.7(a)0(l)-320.3(c)0(o)19.7(m)0(m)18.4(u)0(n)20.8(i)0(c)19.6(a)0(t)19.6(i)0(o)15(n)-323.6(ga)13.9(p)-323.6(b)0(e)19.7(t)0(w)14.1(e)0(e)18.5(n)-323.6(pa)13.9(ti)20.6(en)19.7(ts)]TJ
-1.0137 -1.1116 TD
[(wi)14.1(th)-284.6(ly)20.7(mp)19.6(he)19.7(de)19.7(ma)-286.8(an)19.7(d)-294.8(h)0(e)19.7(a)0(l)19.5(t)0(h)-284.6(c)0(a)18.5(r)0(e)-285.6(p)0(r)15.1(o)0(f)20.9(e)0(s)19.9(s)0(i)20.9(o)0(n)20.8(a)0(l)13.8(s)-294.6(ha)19.7(s)-294.6(n)0(o)20.8(t)-295(be)19.7(en)]TJ
T*
[(id)15(en)19.7(ti)20.6(e)19.8(d.)-350.1(Fu)21(rt)20.7(he)19.7(rm)19.6(or)20.9(e,)-351.3(it)-348(is)-347.7(no)20.8(t)-358.3(k)0(n)20.8(o)0(w)20(n)-358.2(wh)20(et)19.5(he)19.7(r)-358.2(s)0(p)15.3(e)0(c)18.5(i)0(a)19.6(l)0(i)20.6(z)0(e)18.5(d)]TJ
0 -1.1174 TD
[(ca)18.5(re)-176.1(fo)20.9(r)-179.6(p)0(a)13.9(t)0(i)20.6(e)0(n)19.7(t)0(s)-169.2(w)0(i)14.1(t)0(h)-169.4(l)0(y)20.7(m)0(p)19.6(h)0(e)19.7(d)0(e)19.7(m)0(a)-177.4(w)0(i)19.8(t)0(h)-169.4(a)-180.8(hi)15(st)20.9(or)20.9(y)-179.6(o)0(f)-175(c)0(e)18.5(l)0(l)20.6(u)0(l)20.7(i)0(t)20.6(i)0(s)-174.9(i)0(s)]TJ
0 -1.1116 TD
[(av)13.9(ai)19.5(la)19.6(bl)20.7(e)-434.2(w)0(i)14.1(t)0(h)20.7(i)0(n)-422.8(r)0(e)14(a)0(s)19.9(o)0(n)20.8(a)0(b)19.7(l)0(e)-429.7(t)0(r)20.7(a)0(v)19.7(e)0(l)19.5(i)0(n)20.7(g)-438.8(di)20.7(st)20.9(an)13.9(ce)18.5(.)-435.4(T)0(h)19.6(e)-434.2(la)19.6(ck)-429.6(of)]TJ
T*
[(ac)18.5(ce)12.8(ss)21.2(ib)20.7(il)20.6(it)14.8(y)-248.8(c)0(o)19.7(u)0(l)20.7(d)-254.5(be)-245.3(a)-249.9(b)0(a)19.7(r)0(r)15.1(i)0(e)19.6(r)-248.7(to)-244.2(us)21(in)15(g)-248.8(t)0(e)19.6(l)0(e)13.8(h)0(e)19.7(a)0(l)19.5(t)0(h)-244.2(s)0(y)21(s)0(t)20.9(e)0(m)18.5(s)-254.3(fo)20.9(r)]TJ
T*
[(ly)15(mp)19.6(he)19.7(de)19.7(ma)-160.1(ma)18.4(na)19.7(ge)19.7(me)18.4(nt)14.9(.)-170.5(W)0(e)-161.1(a)0(i)19.6(m)0(e)18.4(d)-173.9(to)-157.8(cl)19.5(ar)13.9(if)20.7(y)-168.1(t)0(h)15(e)-169.3(as)19.9(so)15.3(ci)19.5(at)19.6(io)20.7(n)]TJ
0 -1.1174 TD
[(be)13.9(tw)19.8(ee)18.5(n)-369.7(a)-370.9(hi)20.7(st)20.9(or)20.9(y)-375.5(o)0(f)-359.3(c)0(e)18.5(l)0(l)20.6(u)0(l)20.7(i)0(t)20.6(i)0(s)-365(i)0(n)-359.4(p)0(a)19.7(t)0(i)20.6(e)0(n)19.7(t)0(s)-359.2(w)0(i)14.1(t)0(h)-359.4(l)0(y)20.7(m)0(p)19.6(h)0(e)19.7(d)0(e)19.7(m)0(a)]TJ
0 -1.1116 TD
[(an)13.9(d)-254.5(a)0(c)18.5(c)0(e)18.5(s)0(s)-249.5(t)0(o)-244.2(s)0(p)21(e)0(c)18.5(i)0(a)13.8(l)0(i)20.6(z)0(e)18.5(d)-254.5(ca)18.5(re)-251(af)19.7(te)19.6(r)-254.5(a)0(d)13.9(j)0(u)20.7(s)0(t)20.9(i)0(n)20.7(g)-260.3(fo)20.9(r)-254.5(c)0(o)19.7(n)0(f)15.1(o)0(u)20.8(n)0(d)20.8(i)0(n)20.7(g)]TJ
T*
[(fa)14(ct)19.5(or)20.9(s)-271.6(u)0(s)21(i)0(n)20.7(g)-271.8(th)20.7(e)-273(n)0(a)19.7(t)0(i)20.6(o)0(n)20.8(a)0(l)-262.7(d)0(a)19.7(t)0(a)19.6(b)0(a)19.7(s)0(e)-262.4(o)0(f)-261.4(t)0(h)20.7(e)-273(LI)19.7(MP)20.1(RI)19.8(NT)-263.5(st)20.9(ud)15.1(y.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 262.0912 Tm
[(Materials)-339(and)-331.9(Methods)]TJ
/F10 1 Tf
0 -1.8336 TD
[(Study)-338.6(design)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 229.2094 Tm
-.0194 Tc
[(We)-338.4(conduc)-4.4(ted)-337.3(t)2.4(his)-337.1(s)2.7(e)-4.4(c)1.4(ondary)-331.5(a)-4.4(n)2.5(alysis)-331.3(of)-331.5(the)-338.4(n)2.5(ational)-337.4(d)2.5(ata-)]TJ
-1.0137 -1.1116 TD
-.0215 Tc
[(b)-5.3(a)-.7(s)-5.1(e)-277.2(of)-281.7(LI)-5.3(MPR)-6.3(I).5(NT)-6.5(,)-278.4(w)-.4(hi)-5.4(ch)-281.8(was)-281.6(a)-282.9(cro)-5.3(s).6(s)-5.1(-).5(se)-6.5(cti)-5.4(ona)-6.5(l)-276.2(e)-6.5(pid)-5.3(e)-.7(mi)-5.4(olo)-5.3(g).4(-)]TJ
0 -1.1174 TD
-.0194 Tc
[(ical)-193.4(study)]TJ
7.3823 0 0 6.5614 95.5842 211.6913 Tm
0 Tc
(7)Tj
9.843 0 0 9.843 100.97 207.2692 Tm
-.0215 Tc
[(amo)-5.3(n).4(g)-195.4(J).6(a)-6.5(p).4(an)-5.3(ese)-196.5(p).4(a)-6.5(tie)-6.5(nts)-195.2(w)-6.2(ith)-195.4(ly)-5.3(mph)-5.3(e)-.7(dem)-6.5(a)-190.8(i)-5.4(n)-189.6(2)-5.3(014)-5.3(.)]TJ
7.3823 0 0 6.5614 295.1999 211.6913 Tm
0 Tc
(5)Tj
/F10 1 Tf
8.9663 0 0 8.9663 59.7543 182.6078 Tm
[(Patient)-337.7(population)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 166.1669 Tm
.0123 Tc
[(In)-242.2(th)5.4(is)-242(stu)5.4(d)-.3(y)5.4(,)-244.6(th)5.4(e)-249.1(t)5.3(ar)5.5(get)-242.4(p)5.4(opu)5.4(lati)5.3(on)-242.2(in)5.4(clu)5.4(d)-.3(ed)-248(p)5.4(a)-1.5(t)5.3(i)-.4(ent)5.3(s)-247.8(wh)5.4(o)]TJ
-1.0137 -1.1116 TD
.0113 Tc
[(reg)4.4(u)-1.3(l)4.3(a)-2.5(r)4.5(l)-1.4(y)-629.1(v)4.4(isi)4.3(t)-1.4(ed)-629.1(lymp)4.4(hed)4.4(e)-2.5(ma)-630.3(clin)4.4(ics.)-631.5(Two)-629.1(s)4.6(peci)4.3(al)4.3(ized)]TJ
0 -1.1174 TD
.0116 Tc
[(lymp)4.7(hed)4.7(e)-2.2(ma)-428.4(cl)4.6(ini)4.6(c)-2.2(s)-427(i)-1.1(n)-427.2(t)-1.1(h)4.7(e)-434.2(r)4.8(ural)-427.4(a)-2.2(reas)-427(of)-427.2(Japan)-433(w)3.9(er)4.8(e)-434.2(i)4.6(n-)]TJ
0 -1.1116 TD
[(cl)4.7(uded)-242.8(i)-1(n)-242.8(t)4.7(he)-244(LIMPRINT)-244(stu)4.8(d)-.9(y)4.8(.)-245.2(We)-244(in)4.8(cl)4.7(ud)4.8(ed)-242.8(p)4.8(a)-2.1(ti)4.7(en)4.8(ts)-242.6(o)4.8(l)-1(der)]TJ
T*
.0074 Tc
[(t)-5.3(h)-5.2(an)-500.5(18)-500.5(y)-5.2(e)-.6(a)-6.4(r).6(s)-5(,)-502.9(wh)-5.2(o)-500.5(h).5(a)-6.4(d)-494.8(l)-5.3(y)-5.2(mp)-5.2(he)-6.4(de)-6.4(ma)-501.7(fo)-5.2(r)-500.5(l).4(o)-5.2(n)-5.2(g).5(e)-6.4(r)-500.5(th)-5.2(an)-500.6(3)]TJ
0 -1.1174 TD
.0125 Tc
[(mo)5.6(nt)5.5(hs,)-457.5(a)4.5(nd)-460.9(wer)5.7(e)-462.1(able)-456.3(to)-455.1(un)5.6(der)5.7(s).1(t)5.5(a)-1.3(n)5.6(d)-460.9(th)5.6(e)-462.1(c)4.5(on)5.6(ten)5.6(t)-461(o)5.6(f)-460.9(th)5.6(e)]TJ
0 -1.1116 TD
.0116 Tc
[(stu)4.7(d)-1(y)4.7(,)-395(as)-392.5(descri)4.6(bed)-386.9(i)-1.1(n)-392.7(t)4.6(he)-388.1(inf)4.8(o)-1(r)4.8(m)-2.2(ati)4.6(o)-1(n)-392.7(s)4.9(heet,)-389.2(a)3.6(nd)-392.7(p)4.7(r)-1(o)4.7(v)-1(id)4.7(e)]TJ
T*
.0124 Tc
[(inf)5.6(o)-.2(r)5.6(m)-1.4(ed)-184.5(co)5.5(ns)5.7(en)5.5(t.)-181.1(We)-179.9(ex)5.5(clu)5.5(d)-.2(ed)-184.5(p)5.5(a)-1.4(ti)5.4(en)5.5(ts)-184.3(u)5.5(n)-.2(wil)5.4(lin)5.5(g)-184.5(o)-.2(r)-178.7(u)-.2(n)5.5(a)-1.4(bl)5.4(e)]TJ
0 -1.1174 TD
[(to)-443.7(part)5.4(ici)5.4(p)-.2(ate)-444.9(f)-.2(o)5.5(r)-443.7(any)-443.7(r)5.6(eason)5.5(,)-446(th)5.5(os)5.7(e)-450.6(r)5.6(ecei)5.4(vi)5.4(ng)-443.7(en)5.5(d-o)5.5(f-)5.6(li)5.4(fe)]TJ
0 -1.1116 TD
.0117 Tc
[(care,)-527.4(a)3.7(nd)-525(th)4.8(os)5(e)-532(f)4.9(or)-525(wh)4.8(om)-526.3(parti)4.7(c)-2.1(i)4.7(p)-.9(ati)4.7(o)-.9(n)-525(w)-1.8(as)-530.6(cons)5(id)4.8(ered)]TJ
T*
[(dis)5(a)-2.1(d)4.8(v)-.9(ant)4.7(a)-2.1(geou)4.8(s.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 310.8472 725.7825 Tm
0 Tc
[(Data)-331.3(collection)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 709.3416 Tm
-.0199 Tc
[(W)-6(e)-356.2(u)-19.9(s)1.1(e)-19.9(d)-345.8(t)-19.9(h).8(e)-356.2(d)-19.9(at)-19.9(a)-345.9(o)-19.9(f)-344.6(p)-19.9(at)-19.9(ie)-19.9(nt)-19.9(s)-344.6(a)-19.9(nd)-355.1(t)-19.9(h).8(e)-19.9(i)-.4(r)-355(l)-19.9(ym)-19.9(ph)-19.9(ed)-19.9(em)-19.9(a)-347(c)-19.9(ha)-19.9(r-)]TJ
-1.0137 -1.1116 TD
0 Tc
[(ac)18.5(te)19.5(ri)20.7(st)20.9(ic)13.8(s)-317.7(a)0(s)-314.2(r)0(e)19.7(g)0(i)20.7(s)0(t)15.1(e)0(r)19.7(e)0(d)-314.4(i)0(n)-307.6(t)0(h)15(e)-319(LI)19.7(MP)20.1(RI)14.1(NT)-309.5(na)19.7(ti)20.6(on)15.1(al)-308.8(da)19.7(ta)13.8(ba)19.7(se)19.9(.)]TJ
0 -1.1174 TD
[(Pa)19.8(ti)20.6(en)19.7(t)-231.6(c)0(h)19.7(a)0(r)19.7(a)0(c)18.5(t)0(e)19.6(r)0(i)20.7(s)0(t)15.1(i)0(c)19.6(s)-231.3(as)19.9(se)19.9(ss)21.2(ed)-222.2(in)20.7(cl)19.6(ud)20.8(ed)-222.2(se)19.9(x)-231.5(\()0(m)19.6(a)0(l)19.5(e)-232.6(or)-221(fe)19.7(ma)18.5(le)19.6(\),)]TJ
0 -1.1116 TD
[(ag)19.7(e)-313.3(\()0(y)20.9(e)0(a)18.5(r)0(s)-307.2(o)0(l)20.7(d)0(\))20.9(,)-314.5(ob)20.8(es)19.9(it)20.6(y)-312.1(\()0(u)15.1(n)0(d)20.8(e)0(r)19.7(w)0(e)18.8(i)0(g)20.7(h)0(t)20.7(,)-314.4(no)20.8(rm)19.6(al)-303(we)18.8(ig)15(ht)20.7(,)-308.7(o)0(b)15.1(e)0(s)19.9(e)0(,)]TJ
T*
[(an)19.7(d)-456.1(m)15(or)15.1(bi)20.7(dl)20.7(y)-456.1(o)0(b)20.8(e)0(s)19.9(e)0(\))19.7(,)-452.7(hi)14.9(st)20.9(or)20.9(y)-456.1(o)0(f)-445.7(c)0(e)18.5(l)0(l)20.6(u)0(l)20.7(i)0(t)20.6(i)0(s)-445.6(\()0(y)20.9(e)0(s)-446.7(o)0(r)-445.7(n)0(o)20.8(\))0(,)-442.2(a)0(n)19.7(d)]TJ
0 -1.1174 TD
[(hi)20.7(st)20.9(or)20.9(y)-335.2(o)0(f)-324.7(c)0(e)18.5(l)0(l)20.6(u)0(l)20.7(i)0(t)14.8(i)0(s)-324.7(w)0(i)19.8(t)0(h)20.7(i)0(n)-324.9(a)-330.6(ye)13.9(ar)-320.1(\(y)15.1(es)-325.7(or)-318.9(no)15.1(\).)-321.3(Th)19.6(e)-336.3(f)0(o)20.9(l)0(l)20.6(o)0(w)20(i)0(n)20.7(g)]TJ
0 -1.1116 TD
[(ly)20.7(mp)19.6(he)19.7(de)19.7(ma)-332.9(ch)19.7(ar)19.7(ac)12.8(te)19.6(ri)20.7(st)20.9(ic)19.6(s)-346.5(w)0(e)18.8(r)0(e)-331.6(a)0(s)19.9(s)0(e)19.9(s)0(s)15.5(e)0(d)19.7(:)-341(ed)19.7(em)18.5(a)-347.8(t)0(y)20.7(p)0(e)-331.7(\()0(p)20.9(r)0(i)20.7(-)]TJ
T*
[(ma)18.4(ry)-203.8(or)-209.5(se)19.9(co)19.7(nd)20.8(ar)19.7(y\))15.1(,)-216.5(e)0(d)19.7(e)0(m)18.5(a)-215.4(lo)20.7(ca)18.5(ti)20.6(on)-209.5(\(u)20.9(pp)20.8(er)-210.7(ex)19.7(tr)20.8(em)18.4(it)20.6(y)-220(o)0(r)-203.8(l)0(o)20.7(w)0(e)18.8(r)]TJ
T*
[(ex)19.7(tr)20.7(em)18.5(it)20.6(y\))20.9(,)-406.6(e)0(d)19.7(e)0(m)18.5(a)-405.4(du)15.1(ra)19.7(ti)20.6(on)-393.9(\(3)20.9(6)-399.6(m)15(o)0(n)15.1(t)0(h)20.7(s)0(,)-396(6)-404.3(mo)19.6(nt)20.7(hs)21(1)-399.6(ye)19.7(ar)19.7(,)]TJ
0 -1.1174 TD
[(1)20.8(2)-479.1(y)0(e)19.7(a)0(r)19.7(s)0(,)-470.9(2)0()20.8(5)-479.1(ye)13.9(ar)19.7(s,)-470.9(5)20.8(10)-468.7(ye)19.7(ar)19.7(s,)-470.9(or)]TJ
/F7 1 Tf
16.0523 0 TD
()Tj
/F5 1 Tf
.5414 0 TD
[(10)-474.5(ye)19.7(ar)19.7(s\))21.1(,)-481.5(s)0(e)19.9(v)0(e)19.7(r)0(i)20.7(t)0(y)]TJ
-16.5937 -1.1116 TD
[(cl)19.5(as)19.9(si)20.9(c)19.8(at)13.8(io)20.7(n)-329.4(a)0(c)18.5(c)0(o)19.7(r)0(d)15.1(i)0(n)20.7(g)-329.4(to)-324.9(th)20.7(e)-336.3(I)0(n)20.9(t)0(e)19.5(r)0(n)20.9(a)0(t)19.5(i)0(o)20.7(n)0(a)19.7(l)-335.3(So)21(ci)19.5(et)19.5(y)-335.2(o)0(f)-318.9(L)0(y)19.6(m)0(-)]TJ
T*
[(ph)20.8(ol)20.7(og)20.8(y)-398.5(\()0(I)15.1(S)0(L)19.8(\))-398.5(\(I)20.9(,)-400.8(I)0(I)20.9(,)-400.8(la)19.6(te)-389.4(II)15.1(,)-395.1(o)0(r)-393.8(I)0(I)20.9(I)0(\))20.9(,)-400.8(pr)20.9(oc)19.7(ed)19.7(ur)20.9(es)-394.8(in)20.7(cl)19.5(ud)20.8(ed)-389.3(in)]TJ
0 -1.1174 TD
[(CD)18.9(T)-324.8(\()0(p)20.9(h)0(y)20.8(s)0(i)15.1(o)0(t)20.7(h)0(e)19.7(r)0(a)19.7(p)0(y)20.8(,)-326(su)21(rg)20.9(er)13.9(y,)-315.6(sk)21(in)-313.4(ca)18.5(re)-320.1(ad)19.7(vi)20.7(ce)18.5(,)-326(c)0(o)19.7(m)0(p)19.6(r)0(e)19.7(s)0(s)21.2(i)0(o)20.7(n)]TJ
0 -1.1116 TD
[(ga)19.7(rm)19.6(en)19.7(t/)20.6(st)20.9(oc)13.9(ki)20.7(ng)20.8(s,)-401.8(ex)19.7(er)19.7(ci)19.5(se)-406.3(ad)19.7(vi)20.7(ce)18.5(,)-412.4(a)0(n)13.9(t)0(i)20.6(b)0(i)20.7(o)0(t)20.7(i)0(c)19.5(s)0(,)-401.7(a)0(n)13.9(d)0(/)20.7(o)0(r)-399.6(m)0(a)18.4(s)0(-)]TJ
T*
[(sa)19.9(ge)19.7(\),)-257.9(an)13.9(d)-266(a)0(c)18.5(c)0(e)18.5(s)0(s)-261(t)0(o)-261.5(l)0(y)20.7(m)0(p)19.6(h)0(e)19.7(d)0(e)19.7(m)0(a)-263.8(s)0(p)21(e)0(c)18.5(i)0(a)19.5(l)0(i)20.6(s)0(t)15.1(s)0(.)]TJ
1.0137 -1.1174 TD
[(Access)-367.7(to)-370.9(lymphedema)-368.4(specialists)-372.6(was)-368(dened)-371.6(based)-370.5(on)]TJ
-1.0137 -1.1116 TD
[(the)-528.7(following)-535.3(question:)-535.4()50.8(Is)-527.2(treatment)-539.1(by)-532.1(a)-526.4(lymphedem)-9.1(a)]TJ
T*
[(specialist)-296.9(available)-302.9(for)-297(this)-292.4(patient)-298.4(within)-301.6(a)-296(reasonable)-297.8(trav-)]TJ
0 -1.1174 TD
[(eling)-410.1(distance?)47.7()-410(I)0(n)-405.3(Japan,)-408.5(specialists)-413(in)-405.5(lymphedema)-414.5(out-)]TJ
0 -1.1116 TD
[(patient)-500(clinics)-499.8(mainly)-498.8(include)-499.9(medical)-502.3(professionals)-505.8(who)]TJ
T*
[(work)-443(at)-441.2(lymphedema)-449.1(outpatient)-445.9(clinics)-448(or)-439.9(are)-443.3(certied)-450.1(in)]TJ
T*
[(related)-282.1(lymphedema)-287.8(management.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 310.8472 455.244 Tm
[(Statistical)-336.1(analysis)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 438.803 Tm
[(Categorical)-490.5(variables)-497.3(are)-489.4(expressed)-491(as)-492.7(frequencies)-494.7(and)]TJ
-1.0137 -1.1174 TD
[(proportions,)-355.4(and)-355.8(continuous)-357.8(variables)-359(are)-356.9(presented)-364.7(as)-354.5(me-)]TJ
0 -1.1116 TD
[(dians)-283.1(and)-280.9(interquartile)-283.3(ranges)-285.2(\(IQRs\).)]TJ
1.0137 -1.1116 TD
-.0222 Tc
[(Character)5.5(i)-.4(st)5.4(ics)-299.6(o)-.3(f)-299.7(p)-.3(at)5.4(ients)-299.6(w)-1.1(it)5.4(h)-305.5(a)4.3(nd)-299.8(wit)5.4(hou)5.5(t)-305.7(a)-300.9(hi)5.4(sto)5.5(r)-.2(y)-299.8(o)-.3(f)-299.7(cel)5.4(-)]TJ
-1.0137 -1.1174 TD
-.0216 Tc
[(l)6(u).3(li)6(tis)-270.2(w)5.2(e)-.8(re)-271.5(c)4.9(o).3(m)4.9(p).3(ar)6.1(ed.)-266.9(T)-.9(he)-265.8(chi)6(-).4(sq)6.1(uar)6.1(e)-271.5(tes)6.3(t)-270.5(or)-270.3(Fi)6(she)4.9(rs)-270.2(ex)6.1(ac)4.9(t)-270.5(t).2(es)6.3(t)]TJ
0 -1.1116 TD
[(w)5.3(a)-.7(s)-396.8(p).4(er)6.2(for)6.2(m)-.8(ed)-397(f)6.2(o).4(r)-396.9(cat)6.1(eg)6.2(oric)5(al)-397.1(va)5(ria)5(b).4(le)5(s,)-399.3(a)5(n).4(d)-397(W)-1.8(i)6.1(l).3(co)6.2(xon)-397(r)6.2(a)-.7(nk)6.2(-)]TJ
T*
-.0222 Tc
[(su)5.5(m)-289.5(t)-.4(es)5.7(t)-294.1(w)4.6(as)-288.1(perfor)5.5(m)-1.5(ed)-294(f)5.5(o)-.3(r)-288.2(c)-1.4(o)5.5(n)-.3(tin)5.5(uo)5.5(us)-288(var)5.5(i)-.4(ab)5.5(les)5.7(.)-290.6(Factor)5.5(s)-293.8(a)4.3(sso)5.5(-)]TJ
0 -1.1174 TD
-.022 Tc
[(ciat)5.6(ed)-293.8(wit)5.6(h)-299.6(a)-295(h)-.1(i)5.6(s).1(to)5.7(ry)-293.8(of)-299.5(cel)5.6(l)-.2(ul)5.6(itis)-293.6(were)-295(analy)5.7(zed)-293.8(us)5.9(ing)-293.8(b)-.1(iv)5.7(ari)5.6(a)-1.2(t)5.6(e)]TJ
0 -1.1116 TD
-.0217 Tc
[(and)-500.8(m)-1(u)6(lti)5.9(var)6(i).1(at)5.9(e)-507.8(l)5.9(ogi)5.9(sti)5.9(c)-507.8(r)6(e)-.9(gr)6(ess)6.2(i).1(on)-500.9(an)6(aly)6(s).4(es)6.2(.)-503.2(I).3(n)-500.8(t).1(he)-502(l)5.9(ogi)5.9(sti)5.9(c)]TJ
T*
-.0226 Tc
[(model,)-296.7(t)5(h)-.7(e)-295.6(d)-.7(epen)5.1(dent)-294.5(variable)-295.6(was)-294.2(h)-.7(is)5.3(tor)5.1(y)-300.2(o)5.1(f)-294.4(cel)5(lul)5(iti)5(s,)-296.7(and)-294.4(t)-.8(h)5.1(e)]TJ
T*
-.0224 Tc
[(i)5.2(ndepen)5.3(d)-.5(en)5.3(t)-490.2(v)-.5(ar)5.3(iab)5.3(l)-.6(es)-489.8(were)-491.2(s)5.5(e)-1.6(lected)-490(among)-490(t)5.2(hose)-491.2(t)5.2(hat)-495.9(w)4.4(er)5.3(e)]TJ
0 -1.1174 TD
-.0228 Tc
[(clin)4.9(ically)-260(meanin)4.9(gfu)4.9(l)-265.9(and/)4.8(or)-260(had)]TJ
/F6 1 Tf
12.6829 0 TD
0 Tc
(p)Tj
/F5 1 Tf
.7372 0 TD
-.0211 Tc
[(val)6.5(u).8(es)]TJ
/F7 1 Tf
2.684 0 TD
0 Tc
(<)Tj
/F5 1 Tf
.5241 0 TD
-.022 Tc
[(0.05)-259.2(in)-259.2(th)5.7(e)-260.4(b)-.1(iv)5.7(ari)5.6(a)-1.2(te)]TJ
-16.6283 -1.1116 TD
[(anal)5.5(ysi)5.5(s)0(.)-181(M)-1.1(u)5.6(lti)5.5(col)5.5(lin)5.6(ear)5.6(ity)-178.7(was)-184.3(e)4.4(xamin)5.6(e)-1.3(d)-178.7(b)-.2(y)-178.7(c)-1.3(or)5.6(rel)5.5(a)-1.3(ti)5.5(on)-178.7(analys)5.8(is.)]TJ
1.0137 -1.1116 TD
0 Tc
[(Statistical)-499.8(analysis)-500.6(was)-494.7(performed)-497.2(using)-500.8(Stata/SE)-496.2(14.2)]TJ
-1.0137 -1.1174 TD
[(\(StataCorp.,)-245.9(College)-247.5(Station,)-248.7(TX,)-243.9(USA\),)-245.5(and)-246.4(a)]TJ
/F6 1 Tf
18.8227 0 TD
(p)Tj
/F5 1 Tf
.743 0 TD
(value)Tj
/F7 1 Tf
2.4248 0 TD
(<)Tj
/F5 1 Tf
.5472 0 TD
(0.05)Tj
-22.5377 -1.1116 TD
[(was)-281.6(selected)-284.2(as)-279.6(the)-281.1(level)-284.6(of)-278.6(signicance.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 310.8472 250.4125 Tm
[(Ethical)-332.5(considerations)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 233.9716 Tm
[(The)-362.8(study)-362.5(protocol)-361.6(was)-362.3(approved)-362.4(by)-365.1(the)-361.7(Medical)-363.7(Ethics)]TJ
-1.0137 -1.1116 TD
[(Committee)-620.9(of)-624.2(Kanazawa)-626.9(University)-623.7(\(#525-2\).)-622.7(Informed)]TJ
0 -1.1174 TD
[(consent)-240.4(was)-235.5(obtained)-241.8(from)-241.7(each)-238.3(patient)-240.8(or)-238.3(his)-233.6(or)-238.3(her)-240.6(proxies.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 188.0503 Tm
(Results)Tj
/F10 1 Tf
0 -1.8336 TD
[(Patient)-331.4(and)-335.7(lymphedema)-336.1(characteristics)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 155.2252 Tm
[(We)-414.6(collected)-412.4(the)-419.3(data)-410(of)-416.9(113)-412.2(patients,)-417.9(of)-411.1(whom)-415.4(85.7%)]TJ
-1.0137 -1.1174 TD
[(were)-209.2(female.)-210.7(The)-207.3(median)-211.9(age)-207.2(was)-212.5(73)-203.8(\(IQR)-207.8(6580\))-208.2(years.)-212.6(The)]TJ
0 -1.1116 TD
[(proportion)-627.5(of)-630(lower)-629.7(extremity)-630.1(lymphedema)-633.4(was)-633(82.7%)]TJ
T*
(\()Tj
/F6 1 Tf
.3341 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(91\),)-294.7(and)-292.4(98.2%)-296.9(of)-290.1(patients)-299.3(had)-292.4(secondary)-295.4(lymphedema.)]TJ
-1.7164 -1.1174 TD
[(The)-230.3(proportion)-230.1(of)-226.8(patients)-236(who)-228.8(had)-229.1(a)-232.7(history)-226.6(of)-232.6(cellulitis)-232.8(was)]TJ
0 -1.1116 TD
[(31.9%)-279.6(\()]TJ
/F6 1 Tf
3.1966 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(36\))-285.5(\(Table)-280.9(1\).)]TJ
-3.5653 -1.1116 TD
[(T)15(h)16.2(e)-209.6(d)16.2(u)16.2(r)0(a)25.5(t)0(i)26.3(o)16.2(n)-208.4(o)16.2(f)-208.4(e)15(de)25.4(m)15(a)-209.6(r)16.2(a)0(n)25.4(g)16.2(ed)-193.4(fr)26.7(om)-193.5(le)25.3(s)16.4(s)-208.3(th)26.5(a)15(n)-208.4(6)-208.5(m)15(o)16.2(n)0(t)26.5(h)16.2(s)-208.2(t)16(o)-208.5(1)16.2(0)]TJ
-1.0137 -1.1174 TD
[(y)16.2(e)15(ar)25.5(s)-329.2(o)16.2(r)-329.4(l)16.1(on)26.6(g)16.2(e)0(r)25.5(.)-326(Ap)25.7(p)16.2(r)0(o)26.6(x)16.2(im)25.2(a)15(t)0(e)25.3(l)16.1(y)-329.4(h)16.2(al)25.3(f)-329.4(o)16.2(f)-329.4(t)16.1(h)16.2(e)-330.6(p)16.2(a)0(t)25.3(i)16(en)25.4(t)16.1(s)-329.2(ha)25.4(d)-323.6(l)0(y)26.5(m)15(-)]TJ
0 -1.1116 TD
[(p)16.2(h)0(e)25.4(d)16.2(em)24.2(a)-365.1(f)0(o)26.6(r)-369.7(m)15(o)16.2(re)-354.7(th)26.5(a)15(n)-369.7(5)-369.7(y)16.2(e)15(a)0(r)25.5(s)0(,)-355.7(n)16.2(am)24.2(e)15(l)16.1(y)-369.7(5)16.2(1)26.6(0)-369.7(y)16.2(ea)24.3(r)16.2(s)-369.5(\()]TJ
/F6 1 Tf
21.7083 0 TD
(n)Tj
/F7 1 Tf
.6566 0 TD
(=)Tj
/F5 1 Tf
.7027 0 TD
-.0162 Tc
[(31)-16.2(,)]TJ
-23.0676 -1.1116 TD
0 Tc
[(2)16.2(7)0(.)30(9)0(%)25.5(\))-289(a)15(n)16.2(d)-289.1(1)16.2(0)-289.1(y)16.2(ea)24.3(r)16.2(s)-288.9(or)-272.9(lo)26.5(n)16.2(g)0(e)25.4(r)-289(\()]TJ
/F6 1 Tf
12.6598 0 TD
(n)Tj
/F7 1 Tf
.6508 0 TD
(=)Tj
/F5 1 Tf
.7084 0 TD
[(2)16.2(8)0(,)-275.2(2)16.2(5.)30(2%)25.5(\).)-275.2(L)15(y)16.2(mp)25.4(h)16.2(e)0(d)25.4(e)15(m)14.9(a)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(UNREASONABLE)-344.6(DISTANCE)-332.4(WITH)-335.9(LYMPHEDEMA)-337.8(PATIENTS)-336.7(AND)-337.2(SPECIALISTS)-336(PRONE)-339.6(TO)-331.2(CELLULITIS)-2421.2(443)]TJ
ET
endstream
endobj
31 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 62.022 262.8849 Tm
0 0 0 rg
0 Tc
0 Tw
[(se)25.6(v)16.2(e)0(r)25.5(i)16.1(ty)-255.8(a)15(c)15(c)0(o)25.4(r)16.2(di)26.5(n)16.2(g)-266(to)-250(th)26.5(e)-267.2(I)16.2(SL)-256.7(c)15(l)16.1(as)25.6(s)16.4(i)0()26.6(c)0(a)24.3(t)16.1(io)26.5(n)-266(w)15.3(as)-250.8(at)-256.9(a)15(p)16.2(pr)26.6(o)16.2(x)0(i)26.5(m)15(a-)]TJ
0 -1.1174 TD
-.0156 Tc
[(te)-15.6(l)9.7(y)-385.3(s)-15.6(t)11.1(ag)-15.6(e)-376.1(I).6(I)-385.3(\()]TJ
/F6 1 Tf
5.5581 0 TD
0 Tc
(n)Tj
/F7 1 Tf
.6508 0 TD
(=)Tj
/F5 1 Tf
.7027 0 TD
[(28)26.6(,)-372(4)16.2(1)16.2(.)13.9(2%)25.5(\))-369.7(o)16.2(r)-369.7(I)0(I)-359.2(l)16.1(at)25.3(e)15(r)-369.7(\()]TJ
/F6 1 Tf
9.4459 0 TD
(n)Tj
/F7 1 Tf
.6508 0 TD
(=)Tj
/F5 1 Tf
.7084 0 TD
-.0159 Tc
[(32,)-387.9(47)-15.9(.)8.4(1).3(%\))-15.9(.)-371.7(T)-.9(h)-15.9(e)]TJ
-17.7169 -1.1116 TD
0 Tc
[(a)15(d)0(m)25.4(i)16.1(ni)26.5(st)26.7(e)15(r)0(e)25.5(d)-306.4(C)15.2(D)15.3(T)-307.6(i)16.1(nc)25.4(l)16.1(u)0(d)26.6(e)0(d)-291.3(s)0(k)26.8(i)16.1(n)-306.4(c)15(ar)25.5(e)-307.5(a)15(dv)26.6(i)16.1(c)0(e)-292.5(\()]TJ
/F6 1 Tf
18.3274 0 TD
(n)Tj
/F7 1 Tf
.6508 0 TD
(=)Tj
/F5 1 Tf
.7027 0 TD
[(59)26.6(,)-302.9(5)0(2)26.6(.)13.9(1%)25.5(\))16.2(,)]TJ
-19.6809 -1.1116 TD
[(c)15(o)0(m)25.4(p)16.2(re)25.5(ss)27(i)16.1(o)0(n)-537.9(b)16.2(an)25.4(d)16.2(a)0(g)25.4(e)15(/s)26.7(to)26.5(c)15(k)0(i)26.5(n)0(g)26.6(s)-548.1(\()]TJ
/F6 1 Tf
13.5238 0 TD
(n)Tj
/F7 1 Tf
.6508 0 TD
(=)Tj
/F5 1 Tf
.7027 0 TD
[(63)26.6(,)-550.6(5)16.2(5.)24.3(8)16.2(%)15.1(\),)-540.1(m)15(u)16.2(lt)26.3(i)16.1(l)0(a)25.3(y)16.2(er)]TJ
-14.8773 -1.1174 TD
-.0254 Tc
[(b)-9.2(a)-25.4(nd)-25.4(ag)-9.2(e)-25.4(s)-253.2(\()]TJ
/F6 1 Tf
4.1873 0 TD
0 Tc
(n)Tj
/F7 1 Tf
.6566 0 TD
(=)Tj
/F5 1 Tf
.7027 0 TD
[(4)16.2(7)0(,)-229.2(3)16.2(8)16.2(.)13.9(1%)25.5(\))16.2(,)-239.6(l)16.1(y)0(m)25.4(p)16.2(ha)25.4(t)16.1(i)0(c)-228.1(d)16.2(ra)25.5(in)26.5(a)15(g)0(e)-228(\()]TJ
/F6 1 Tf
12.8441 0 TD
(n)Tj
/F7 1 Tf
.6566 0 TD
(=)Tj
/F5 1 Tf
.7027 0 TD
-.0162 Tc
[(69)-16.2(,)-239.6(6)-16.2(1)10.4(.)-2.3(1)-16.2(%)9.3(\),)]TJ
-19.75 -1.1116 TD
-.0254 Tc
[(a)-10.4(n)-25.4(d)-373.2(e)-25.4(xe)-10.4(r)-25.4(c).1(i)-9.3(s)-25.4(e)-374.1(a)-25.4(dv)-9.2(i)-25.4(c)-.1(e)-390.5(\()]TJ
/F6 1 Tf
8.5704 0 TD
0 Tc
(n)Tj
/F7 1 Tf
.6508 0 TD
(=)Tj
/F5 1 Tf
.7084 0 TD
[(4)16.2(3)16.2(,)-366.3(4)16.2(1)16.2(.)13.9(6%)25.5(\))16.2(.)-360.5(To)-349(pr)26.6(e)15(v)0(e)25.4(n)16.2(t)-364.1(a)15(nd)26.6(/)16.1(o)0(r)-347.7(t)0(r)26.5(e)15(at)]TJ
-9.9297 -1.1116 TD
[(c)15(e)0(l)25.3(l)16.1(ul)26.5(it)26.3(i)16.1(s)0(,)-177.1(p)16.2(at)25.3(i)16.1(e)0(n)25.4(t)16.1(s)-191(r)0(e)25.5(c)15(ei)25.3(v)16.2(e)0(d)-176.2(c)15(el)25.3(lu)26.5(l)16.1(i)0(t)26.3(i)16.1(s)-191(a)15(dv)26.6(i)16.1(c)0(e)-177.3(\()]TJ
/F6 1 Tf
17.0718 0 TD
(n)Tj
/F7 1 Tf
.6508 0 TD
(=)Tj
/F5 1 Tf
.7027 0 TD
[(56)26.6(,)-187.7(4)0(9)26.6(.)13.9(6)16.2(%)0(\))-176(a)15(nd)]TJ
-18.4253 -1.1116 TD
-.0265 Tc
[(a)-11.5(n)-26.5(ti)-26.5(bi)-10.4(o)-26.5(t)0(i)-10.4(c)-26.5(s)-317.7(\()]TJ
/F6 1 Tf
4.6711 0 TD
0 Tc
(n)Tj
/F7 1 Tf
.6508 0 TD
(=)Tj
/F5 1 Tf
.7027 0 TD
[(14)26.6(,)-302.9(1)0(2)26.6(.)13.9(4)16.2(%)15.1(\).)-292.5(T)15(h)0(e)-291.3(p)16.2(ro)26.6(po)26.6(r)16.2(t)0(i)26.3(o)16.2(n)-306.4(o)16.2(f)-306.3(p)16.2(at)25.3(i)16.1(e)0(n)25.4(t)16.1(s)-306.2(h)16.2(av)25.4(i)16.1(n)0(g)]TJ
-6.0247 -1.1174 TD
[(a)15(c)0(c)24.3(e)15(ss)-255.2(t)16.1(o)-266(ly)26.5(m)15(p)0(h)26.6(e)15(de)25.4(m)15(a)-267.2(sp)26.8(e)15(c)0(i)25.3(a)15(li)26.3(s)16.4(t)0(s)-255.6(w)15.3(as)-256.6(5)16.2(7)16.2(.)13.9(1%)-256.7(\()]TJ
/F6 1 Tf
18.2698 0 TD
(n)Tj
/F7 1 Tf
.6508 0 TD
(=)Tj
/F5 1 Tf
.7084 0 TD
-.0162 Tc
[(60\))-16.2(.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 62.022 149.726 Tm
0 Tc
[(Comparison)-335(of)-336.7(characteristics)-330.3(between)-338.3(patients)]TJ
0 -1.2203 TD
[(with)-336.5(and)-329.4(without)-336.3(history)-333(of)-336.7(cellulitis)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 122.3433 Tm
[(The)-368.5(comparison)-371.6(of)-365(characteristics)-374.9(betwe)-8.8(en)-366.2(patients)-368.4(with)]TJ
-1.0137 -1.1174 TD
[(and)-280.9(without)-285.4(cellulitis)-290.4(history)-278.4(is)-284.4(shown)-282.7(in)-284.6(Table)-285.6(2.)-281(Access)-287(to)]TJ
0 -1.1116 TD
[(lymphedema)-472.1(specialists)-476.3(among)-468.7(patients)-472.1(with)-472.1(a)-468.8(history)-468.5(of)]TJ
T*
[(cellulitis)-417.1(was)-419.8(signicantly)-418.9(lower)-416.6(\()]TJ
/F6 1 Tf
14.2553 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(11,)-414.6(34.4%\))-413.2(than)-414.6(that)]TJ
-15.6434 -1.1174 TD
[(among)-244(patients)-253.2(without)-245.1(a)-244.2(history)-243.9(of)-244.1(cellulitis)-250.1(\()]TJ
/F6 1 Tf
18.4944 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(49,)-241.8(67.1%\))]TJ
-19.8825 -1.1116 TD
(\()Tj
/F6 1 Tf
.5011 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(0.002\).)-392.5(Multicollin)-9.2(earity)-395.1(was)-391(not)-395.1(observed)-391.1(among)-393.8(the)]TJ
-1.8834 -1.1116 TD
[(independent)-286.6(variables)-284.1(that)-282.3(had)]TJ
/F6 1 Tf
12.6138 0 TD
(p)Tj
/F5 1 Tf
.7776 0 TD
(values)Tj
/F7 1 Tf
2.8453 0 TD
(<)Tj
/F5 1 Tf
.72 0 TD
(0.05.)Tj
/F10 1 Tf
8.9663 0 0 8.9663 313.0582 334.0345 Tm
[(Association)-340.4(between)-331.9(history)-333(of)-336.7(cellulitis)-337.7(in)-330.2(patients)]TJ
0 -1.2203 TD
[(with)-336.5(lymphedema)-336.1(and)-335.7(having)-330.3(access)-335.7(to)-330.4(specialists)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 306.6519 Tm
[(History)-527(of)-526.3(cellulitis)-532.3(among)-526.3(patients)-529.7(with)-523.9(lymphedema)]TJ
-1.0137 -1.1116 TD
[(was)-512(negatively)-516(associated)-510.9(with)-512.4(access)-512(to)-509.2(specialists)-516.6(\(ad-)]TJ
0 -1.1174 TD
[(justed)-549.2(odds)-539.9(ratio)-548.3([AOR])]TJ
/F7 1 Tf
10.6958 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.28,)-540.1(95%)-545.8(condence)-544.3(interval)]TJ
-11.4157 -1.1116 TD
([CI])Tj
/F7 1 Tf
1.8373 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.110.74,)Tj
/F6 1 Tf
4.579 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.009\).)-329.1(Furthermore,)-335.8(a)-330.6(longer)-330.4(duration)]TJ
-8.5244 -1.1116 TD
[(of)-376.5(lymphedema)-380(was)-379.5(signicantly)-378.6(associated)-378.4(with)-374.2(a)-376.6(history)]TJ
T*
[(of)-549.3(cellulitis)-549.6(\(AOR)]TJ
/F7 1 Tf
8.0002 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(4.10,)-545.8(95%)-545.8(CI)]TJ
/F7 1 Tf
6.088 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(1.5311.0,)Tj
/F6 1 Tf
4.7978 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
(0.005\))Tj
-21.7083 -1.1174 TD
[(\(Tabl)-8(e)-278.7(3\).)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 313.0582 215.4897 Tm
(Discussion)Tj
/F5 1 Tf
9.843 0 0 9.843 323.0361 199.0488 Tm
[(In)-301.7(this)-304(secondary)-301.2(analysis)-304.8(of)-301.7(the)-298.3(LIMPRINT)-307.5(national)-305.3(da-)]TJ
-1.0137 -1.1174 TD
[(tabase,)-468.5(we)-465(claried)-467.4(the)-459.6(relationship)-465.1(between)-467.2(a)-463(history)-462.8(of)]TJ
0 -1.1116 TD
[(cellulitis)-307.7(in)-307.6(patients)-305.1(with)-305(lymphedema)-305.1(and)-304(having)-307.4(access)-304.6(to)]TJ
T*
[(specialists.)-191.8(Pa)19.8(ti)14.8(en)19.7(ts)-163.4(wi)19.8(th)-169.4(a)-175(h)0(i)20.7(s)0(t)20.9(o)0(r)20.9(y)-179.6(of)-163.4(ce)18.5(ll)20.6(ul)20.7(it)14.8(is)-163.4(ha)19.7(d)-173.9(s)0(i)15.2(g)0(n)20.8(i)0()20.9(c)0(a)18.5(n)0(t)20.7(l)0(y)]TJ
T*
[(le)13.8(ss)-439.5(ac)18.5(ce)18.5(ss)-439.5(to)-434.3(ly)15(m)15(p)0(h)15.1(e)0(d)19.7(e)0(m)18.4(a)-445.8(sp)21(ec)12.8(ia)19.5(li)20.6(st)20.9(s,)-442.1(th)20.7(us)-439.7(su)21(gg)20.8(es)19.9(ti)20.6(ng)-439.9(th)20.7(e)]TJ
0 -1.1174 TD
[(ne)13.9(ce)18.5(ss)21.2(it)20.6(y)-289.1(t)0(o)-278.8(i)0(m)19.5(p)0(r)15.1(o)0(v)20.8(e)-290.2(ac)18.5(ce)18.5(ss)-278.3(an)19.7(d)-289.1(c)0(o)19.7(m)0(m)18.4(u)0(n)20.8(i)0(c)19.6(a)0(t)19.5(i)0(o)15(n)-289.1(be)19.7(tw)19.8(ee)18.5(n)-289.1(p)0(a)19.7(-)]TJ
0 -1.1116 TD
[(ti)14.8(en)19.7(ts)-261.3(wi)19.8(th)-261.5(ly)20.7(mp)19.6(he)19.7(de)19.7(ma)-258(an)19.7(d)-271.8(s)0(p)21(e)0(c)18.5(i)0(a)13.8(l)0(i)20.6(s)0(t)20.9(s)-271.6(to)-261.5(pr)20.9(ev)19.7(en)19.7(t)-271.9(c)0(e)18.5(l)0(l)20.6(u)0(l)20.7(i)0(t)20.6(i)0(s)20.9(.)]TJ
1.0137 -1.1116 TD
[(The)-328.2(proportion)-322.2(of)-324.7(patients)-328.1(having)-324.7(access)-327.7(to)-324.9(lymphedema)]TJ
-1.0137 -1.1174 TD
[(specialists)-361.1(was)-356.5(more)-352.4(than)-357(double)-353.5(in)-353.7(the)-350.2(group)-356.8(without)-354.6(cel-)]TJ
0 -1.1116 TD
[(luliti)-7.3(s)-340.7(history)-347.6(than)-351.3(in)-342.1(that)-351.4(with)-345.4(cellulitis)-348(history)-347.6(\(67.1%)-349.8(vs.)]TJ
T*
(34.4%,)Tj
/F6 1 Tf
3.116 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.002\).)-283.1(After)-284.1(adjusting)-287.7(for)-279.7(age,)-285.5(ISL)-280.8(severity,)-291.1(and)]TJ
-4.5041 -1.1174 TD
[(lymphedem)-9.1(a)-457.3(duration,)-457.1(history)-462.8(of)-457.2(cellulitis)-463.2(was)-460.2(associated)]TJ
0 -1.1116 TD
[(with)-506.6(less)-506.4(acces)-10(s)-502(t)0(o)-503.4(lymphedema)-512.4(specialists)-510.9(\(AOR)]TJ
/F7 1 Tf
21.5759 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.28,)Tj
/F6 1 Tf
-22.2958 -1.1116 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.009\).)-294.6(The)-293.6(current)-298.1(data)-294.8(are)-299.3(supported)-293.2(by)-295.9(those)-294.6(reported)]TJ
ET
62.022 719.49 239.131 .22668 re
f
62.022 362.438 239.131 .28348 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 77.2724 725.1588 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(1.)Tj
/F9 1 Tf
1.2496 0 TD
[(Participant)-335.5(Characteristics)-339.1(\()]TJ
/F11 1 Tf
13.5038 0 TD
(N)Tj
/F7 1 Tf
.8811 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
(113)Tj
/F9 1 Tf
1.503 0 TD
(\))Tj
/F5 1 Tf
-22.4065 -1.5894 TD
[(Sex)-332.2(\(female\))-14553.1(96)-336(\(85.7\))]TJ
0 -1.0135 TD
[(Age)-333.2(\(years\))-15010.1(73)-336(\(6580\))]TJ
T*
(Obesity)Tj
1.002 -1.0077 TD
[(Underweight)-13559.3(12)-336(\(11.0\))]TJ
0 -1.0135 TD
[(Normal)-331.7(weight)-12665.6(66)-336(\(60.6\))]TJ
T*
[(Obese)-16287.4(23)-336(\(21.2\))]TJ
T*
[(Morbidly)-331.6(obese)-12894.7(8)-335(\(7.3\))]TJ
-1.002 -1.3129 TD
[(Edema)-337.9(type)-333.5(\(secondary\))-9371.9(111)-337(\(98.2\))]TJ
0 -1.0135 TD
[(Edema)-337.9(location)-333.3(\(lower)-336.3(extremity\))-5956.8(91)-336(\(82.7\))]TJ
0 -1.0077 TD
[(Edema)-337.9(duration)]TJ
/F7 1 Tf
1.002 -1.0135 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
[(6)-329.2(Months)-14351.3(18)-336(\(16.2\))]TJ
-.5528 -1.0135 TD
[(6)-329.2(Months1)-337(year)-11840.1(13)-336(\(11.7\))]TJ
T*
[(12)-331.2(Years)-15124.1(7)-335(\(6.3\))]TJ
0 -1.0077 TD
[(25)-331.2(Years)-14623.1(14)-336(\(12.6\))]TJ
0 -1.0135 TD
[(510)-332.2(Years)-14122.1(31)-336(\(27.9\))]TJ
T*
[(10)-330.2(Years)-336.2(or)-336(longer)-11057.9(28)-336(\(25.2\))]TJ
-1.002 -1.313 TD
(ISL)Tj
7.3837 0 0 6.5625 76.8189 548.5038 Tm
(a)Tj
9.845 0 0 9.845 83.3952 544.1384 Tm
(classication)Tj
-1.169 -1.0135 TD
[(Stage)-335.5(I)-16389.8(6)-335(\(8.8\))]TJ
T*
[(Stage)-335.5(II)-15555.8(28)-336(\(41.2\))]TJ
0 -1.0077 TD
[(Stage)-335.5(II)-330.2(later)-13436.6(32)-336(\(47.1\))]TJ
0 -1.0135 TD
[(Stage)-335.5(III)-15723.8(2)-335(\(2.9\))]TJ
-1.002 -1.3187 TD
[(History)-336.2(of)-330.2(cellulitis)-341.4(\(ever\))-9089.5(36)-336(\(31.9\))]TJ
0 -1.0077 TD
[(History)-336.2(of)-330.2(cellulitis)-341.4(\(within)-330.8(1)-335(year\))-5362.7(15)-336(\(15.8\))]TJ
0 -1.0135 TD
[(Categories)-337.1(of)-336(treatment)-336.6(within)-335.5(CDT)]TJ
7.3837 0 0 6.5625 207.9495 475.7668 Tm
(b)Tj
9.845 0 0 9.845 71.8866 461.4235 Tm
[(Physiotherapy)-13058.3(13)-336(\(11.5\))]TJ
T*
[(Debulking/lipedema/lymphatic)-338.9(surgery)-3457.3(9)-335(\(8.0\))]TJ
0 -1.0077 TD
[(Skin)-332.2(care)-335.7(advice)-11987.4(59)-336(\(52.2\))]TJ
0 -1.0135 TD
[(Compression)-336.5(garment)-9880.8(63)-336(\(55.8\))]TJ
T*
[(Multilayer)-336.2(bandage)-10871.1(47)-336(\(38.1\))]TJ
0 -1.0077 TD
[(Exercise)-335.1(advice)-12373.2(43)-336(\(41.6\))]TJ
0 -1.0135 TD
[(Cellulitis)-335.4(advice)-12142.9(56)-336(\(49.6\))]TJ
T*
[(Antibiotics)-14329.3(14)-336(\(12.4\))]TJ
T*
[(Lymphatic)-336.4(drainage)-10641.9(69)-336(\(61.1\))]TJ
-1.002 -1.313 TD
[(Access)-338.2(to)-336.2(lymphedema)-332.6(specialists)]TJ
7.3837 0 0 6.5625 199.1055 373.1527 Tm
(c)Tj
9.845 0 0 9.845 256.8188 368.7873 Tm
[(60)-336(\(57.1\))]TJ
/F6 1 Tf
8.7511 0 0 8.7511 70.0157 350.6456 Tm
(N)Tj
/F5 1 Tf
.9977 0 TD
[(\(%\),)-330.6(median)-335(\(interquartile)-332.9(range\).)]TJ
6.5633 0 0 5.8334 70.0157 345.5999 Tm
(a)Tj
8.7511 0 0 8.7511 72.9637 341.6881 Tm
[(International)-330.3(Society)-334.8(of)-333.1(Lymphology.)]TJ
6.5633 0 0 5.8334 70.0157 336.5858 Tm
(b)Tj
8.7511 0 0 8.7511 73.3039 332.7306 Tm
[(The)-512.1(sum)-517.2(of)-514.5(the)-521.2(percentages)-513.5(exceeds)-519.7(100%)-517.5(as)-515.5(the)-514.7(treatment)]TJ
-1.2892 -1.0236 TD
[(procedures)-337.2(were)-328.9(overlapping.)]TJ
6.5633 0 0 5.8334 70.0157 318.6708 Tm
(c)Tj
8.7511 0 0 8.7511 72.9637 314.759 Tm
[(Is)-240.8(treatment)-251(by)-243.8(a)-246.2(lymphedema)-244.9(specialist)-242.7(available)-249.6(for)-246.3(this)-243.9(patient)]TJ
-1.2503 -1.0236 TD
[(within)-334.8(a)-330.4(reasonable)-338.6(traveling)-330(distance?)]TJ
.9134 -1.0236 TD
[(CDT,)-246.2(complex)-256.1(decongestive)-245.7(treatment;)-255(ISL,)-246.3(International)-252.5(Society)]TJ
-.9134 -1.0236 TD
[(of)-333.1(Lymphology.)]TJ
ET
313.058 709.512 239.131 .22681 re
f
313.058 414.028 239.131 .22678 re
f
313.058 670.904 239.131 .22675 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 341.0078 725.1588 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(2.)Tj
/F9 1 Tf
1.2496 0 TD
[(Bivariate)-332.2(Analysis)-337.6(for)-332.2(History)]TJ
2.027 -1.0135 TD
[(of)-331.2(Cellulitis)]TJ
/F6 1 Tf
2.3322 -1.8427 TD
(Cellulitis)Tj
.144 -1.0135 TD
(negative)Tj
.0633 -1.0077 TD
(\()Tj
/F5 1 Tf
.334 0 TD
(N)Tj
/F7 1 Tf
.8868 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
(77\))Tj
3.4782 2.0212 TD
(Cellulitis)Tj
.2822 -1.0135 TD
(positive)Tj
-.0749 -1.0077 TD
(\()Tj
/F5 1 Tf
.334 0 TD
(N)Tj
/F7 1 Tf
.8868 0 TD
(=)Tj
/F6 1 Tf
.7141 0 TD
(36\))Tj
/F5 1 Tf
3.697 0 TD
(p)Tj
-22.9132 -1.9003 TD
[(Sex)-338(\(female\))-6301.1(62)-336(\(81.6\))-2121.7(34)-336(\(94.4\))-872.1(0.069)]TJ
0 -1.0077 TD
[(Age)-339(\(years\))-6009.5(95.5)-334.6(\(17.0\))-1373.1(70.5)-334.6(\(2.2\))-1372.1(0.319)]TJ
0 -1.0135 TD
[(Obesity)-18925.9(0.294)]TJ
1.002 -1.0135 TD
[(Underweight)-5814.1(8)-335(\(11.0\))-2622.7(4)-335(\(11.1\))]TJ
T*
[(Normal)-337.5(weight)-4413.6(47)-336(\(64.4\))-2121.7(19)-336(\(52.8\))]TJ
0 -1.0077 TD
[(Obese)-8041.1(15)-336(\(20.6\))-2622.7(8)-335(\(22.2\))]TJ
0 -1.0135 TD
[(Morbidly)-337.3(obese)-4642.7(3)-335(\(4.1\))-3122.7(5)-335(\(13.9\))]TJ
-1.002 -1.3187 TD
[(Edema)-337.9(type)-333.5(\(secondary\))-1626.6(77)-336(\(100.0\))-1621.7(34)-336(\(94.4\))-872.1(0.037)]TJ
0 -1.0077 TD
[(Edema)-337.9(location)-339(\(lower)]TJ
.9962 -1.0135 TD
[(extremity)-335.4(limb\))]TJ
10.5439 1.0135 TD
[(63)-336(\(85.1\))-2121.7(28)-336(\(77.8\))-872.1(0.338)]TJ
-11.5401 -2.027 TD
[(Edema)-337.9(duration)-15569(0.081)]TJ
/F7 1 Tf
1.002 -1.0135 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
[(6)-335(Months)-6099.3(14)-336(\(18.7\))-2622.7(4)-335(\(11.1\))]TJ
-.5528 -1.0077 TD
[(6)-335(Months1)-331.2(year)-3593.9(11)-336(\(14.7\))-2622.7(2)-335(\(5.6\))]TJ
0 -1.0135 TD
[(12)-331.2(Years)-6877.9(7)-335(\(9.3\))-3122.7(0)-335(\(0.0\))]TJ
T*
[(25)-331.2(Years)-6376.9(10)-336(\(13.3\))-2622.7(4)-335(\(11.1\))]TJ
0 -1.0077 TD
[(510)-332.2(Years)-5875.9(18)-336(\(23.4\))-2121.7(13)-336(\(36.1\))]TJ
0 -1.0135 TD
[(10)-336(Years)-336.2(or)-330.2(longer)-2811.7(15)-336(\(19.5\))-2121.7(13)-336(\(36.1\))]TJ
-1.002 -1.3187 TD
(ISL)Tj
7.3837 0 0 6.5625 327.855 487.5023 Tm
(a)Tj
9.845 0 0 9.845 334.4314 483.0802 Tm
[(classication)-14632.9(0.052)]TJ
-1.169 -1.0077 TD
[(Stage)-335.5(I)-8143.6(6)-335(\(15.8\))-2622.7(0)-335(\(0.0\))]TJ
0 -1.0135 TD
[(Stage)-335.5(II)-7309.6(16)-336(\(42.1\))-2121.7(12)-336(\(33.3\))]TJ
T*
[(Stage)-335.5(II)-336(later)-5184.6(16)-336(\(42.1\))-2121.7(16)-336(\(53.3\))]TJ
T*
[(Stage)-335.5(III)-7477.6(0)-335(\(0.0\))-3122.7(2)-335(\(6.7\))]TJ
-1.002 -1.313 TD
[(Access)-338.2(to)-336.2(lymphedema)]TJ
.9962 -1.0135 TD
(specialists)Tj
7.3837 0 0 6.5625 363.4582 424.6865 Tm
(b)Tj
9.845 0 0 9.845 426.6707 430.2991 Tm
[(49)-336(\(67.1\))-2121.7(11)-336(\(34.4\))-872.1(0.002)]TJ
/F6 1 Tf
8.7511 0 0 8.7511 321.0519 402.1794 Tm
(N)Tj
/F5 1 Tf
.9977 0 TD
[(\(%\),)-337(median)-328.5(\(interquartile)-339.4(range\),)-332(chi-square)-336(test,)-331.9(or)]TJ
/F6 1 Tf
21.7479 0 TD
(t)Tj
/F5 1 Tf
.2786 0 TD
(-test.)Tj
6.5633 0 0 5.8334 321.0519 397.1338 Tm
(a)Tj
8.7511 0 0 8.7511 323.9999 393.2219 Tm
[(International)-336.8(Society)-328.4(of)-333.1(Lymphology.)]TJ
6.5633 0 0 5.8334 321.0519 388.1763 Tm
(b)Tj
8.7511 0 0 8.7511 324.3401 384.2645 Tm
[(Is)-240.8(treatment)-244.5(by)-237.4(a)-239.7(lymphedema)-244.9(specialist)-242.7(available)-243.1(for)-239.8(this)-237.4(patient)]TJ
-1.2892 -1.0236 TD
[(within)-334.8(a)-336.9(reasonable)-332.1(traveling)-336.5(distance?)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(444)Tj
49.3883 0 TD
[(DAI)-331.6(ET)-338.7(AL.)]TJ
ET
endstream
endobj
36 0 obj
<>stream
hbd`ab`ddqtqvL),IvLMJ-*Jf!#wʯ'?Y7oQqRʢdMCKSi&-AcJ~RBpeqIjng^r~QA~QbIjcNBȄbԢ2(%
%E)E
i
>y%
y)E
@}ťIř)EzX<̌L|~&%\쒆v=Puf(k
~g0ϹfO_~H}g;?ι$I> Ӏ
endstream
endobj
39 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 59.7543 604.5164 Tm
0 0 0 rg
0 Tc
0 Tw
[(by)-313.2(a)-313.3(systematic)-315.2(review)-315.2(that)-311.1(examined)-313.2(self-care)-319.7(for)-308.5(lymphe-)]TJ
0 -1.1116 TD
(dema)Tj
7.3823 0 0 6.5614 81.1842 597.94 Tm
(13)Tj
9.843 0 0 9.843 90.8787 593.5746 Tm
[(where)-239.1(proper)-238.1(self-care)-239(was)-235.5(found)-235.9(to)-232.7(inuence)-236.9(edema)]TJ
-3.1621 -1.1116 TD
[(control)-372(and)-373.1(decrease)-377.3(the)-367.5(rate)-375.4(of)-365(recurrent)-376.3(cellulitis.)-374.5(Proper)]TJ
0 -1.1174 TD
[(self-care)-239(is)-238.3(related)-236.1(to)-232.7(easy)-236.9(access)-235.5(to)-238.5(health)-233.8(care)-238.2(professionals)]TJ
0 -1.1116 TD
[(and)-390.4(medication.)-393.9(Therefore,)-398.1(patients)-391.5(who)-390.1(have)-386.9(a)-393.9(history)-387.9(of)]TJ
T*
[(cellulitis)-348(would)-334.8(have)-346.6(insufcient)-342.8(self-care)-342.7(to)-336.4(prevent)-344.2(cellu-)]TJ
0 -1.1174 TD
[(litis)-282.3(based)-284.1(on)-278.7(edema)-286.7(control.)]TJ
1.0137 -1.1116 TD
[(Lymphedema)-478.9(management)-479(mainly)-475.8(consists)-476.2(of)-474.5(self-care)]TJ
-1.0137 -1.1116 TD
[(based)-318.7(on)-313.2(CDT)]TJ
7.3823 0 0 6.5614 117.9212 521.2345 Tm
(8)Tj
9.843 0 0 9.843 124.6677 516.8691 Tm
[(and)-315.5(early)-313.2(consultation)-315.4(such)-316.4(as)-314.2(using)-310.7(antibi-)]TJ
-6.5949 -1.1174 TD
[(otics)-392.6(before)-389(cellulitis)-394.1(onset.)]TJ
7.3823 0 0 6.5614 172.5165 510.2928 Tm
(2)Tj
9.843 0 0 9.843 180.0566 505.8707 Tm
[(Some)-392.5(studies)-388.9(have)-386.9(suggested)]TJ
-12.2221 -1.1116 TD
[(that)-242(patients)-241.7(with)-241.7(lymphedema)-241.7(need)-237.1(to)-238.5(live)-242(within)-238.3(a)-238.4(physical)]TJ
T*
[(distance)-283.1(to)-278.8(meet)-278.8(with)-276.2(health)-279.9(care)-278.6(professionals)-287(6)-271.8(monthly,)]TJ
7.3823 0 0 6.5614 291.4582 488.3526 Tm
(13)Tj
9.843 0 0 9.843 59.7543 473.0456 Tm
[(denoting)-321.3(that)-316.8(regular)-321.1(visits)-317.6(provide)-320(consultation)-321.1(and)-315.5(educa-)]TJ
0 -1.1174 TD
[(tional)-428.6(opportunities)-430.5(for)-429.5(patients)-431.8(to)-422.8(improve)-430.7(their)-427.4(self-care)]TJ
0 -1.1116 TD
[(behaviors.)-689.5(However,)-689.1(in)-682(the)-684.2(real-world)-688.3(setting,)-686.4(making)]TJ
T*
[(changes)-373.9(to)-370.9(physical)-374.1(distancing)-370.6(seems)-371.5(difcult)-373(for)-371.9(both)-367.4(pa-)]TJ
0 -1.1174 TD
[(tients)-549.4(and)-545.9(trained)-551.7(professionals,)-549.6(as)-544.6(it)-543.9(may)-547.1(contribute)-549.3(to)]TJ
0 -1.1116 TD
[(physical,)-527.3(social,)-530.8(and)-522.8(emotional)-526.5(aspects)-529.3(for)-521.6(patients)-529.7(with)]TJ
T*
[(chronic)-482.4(illness.)]TJ
7.3823 0 0 6.5614 121.833 411.6471 Tm
(14)Tj
9.843 0 0 9.843 133.9086 407.2818 Tm
[(Therefore,)-484.5(developing)-480.1(feasible)-484.6(and)-476.8(sus-)]TJ
-7.5337 -1.1174 TD
[(tainable)-473.5(systems)-470.4(to)-468.9(support)-474.2(patient)-471.2(adherence)-470.7(and)-471(under-)]TJ
0 -1.1116 TD
[(standing)-632.1(of)-630(self-care)-636.4(regardless)-636.2(of)-624.2(physical)-633.3(distance)-634.4(is)]TJ
T*
(needed.)Tj
1.0137 -1.1174 TD
.0129 Tc
[(Th)-5.5(e)-283.1(C)-6.5(OVI)-5.4(D-)-5.4(19)-287.7(pan)-5.5(d).3(e)-6.6(m)-.9(ic)-288.9(has)-287.5(l).2(e)-6.6(d)-281.9(t)-5.6(o)-281.9(th)-5.5(e)-283.1(p)-5.5(ro)-5.5(gre)-6.6(ss)-287.5(of)-287.7(te)-6.6(l-)]TJ
-1.0137 -1.1116 TD
.0149 Tc
[(e)-4.6(h)2.3(e)-4.6(a)1.1(lth)-285.7(s)2.5(ystems)-291.3(for)-285.7(med)]TJ
10.1313 0 TD
.0147 Tc
[(ic)-4.8(al)-286(consultations)]TJ
7.3823 0 0 6.5614 231.2503 356.8251 Tm
0 Tc
(1)Tj
9.843 0 0 9.843 237.8834 352.4597 Tm
.0195 Tc
[(an)6.9(d)-281.1(h)6.9(as)-280.9(h)6.9(e)0(l)6.8(p)1.1(e)5.7(d)]TJ
-18.097 -1.1116 TD
.0149 Tc
[(improve)-413.6(t)2.2(he)-413.6(se)-4.6(lf-c)-4.6(are)-419.3(b)2.3(ehavio)]TJ
12.8441 0 TD
.0129 Tc
[(rs)-414.2(o)-5.5(f)-414.4(pa)-6.6(ti)-5.6(ent)-5.6(s)-414.2(wi)-5.6(th)-420.2(chr)-5.4(o).3(n)-5.5(i).2(c)]TJ
-12.8441 -1.1116 TD
.0187 Tc
[(il)6(ln)6.1(es)6.3(s.)]TJ
7.3823 0 0 6.5614 88.6677 334.9417 Tm
.0145 Tc
(15)Tj
9.843 0 0 9.843 101.1401 330.5763 Tm
.0129 Tc
[(T)-6.7(h).3(e)-6.6(s).5(e)-496.2(t).2(ec)-6.6(hn)-5.5(ica)-6.6(l)-489.4(a)-6.6(d).3(v)-5.5(a)-.9(nc)-6.6(es)-494.9(wo)-5.5(ul)-5.6(d)-489.3(c)-6.6(ont)-5.6(ri)-5.6(bu)-5.5(te)-496.2(to)]TJ
-4.2046 -1.1174 TD
.0131 Tc
[(l)-5.4(y).5(m)-6.5(phe)-6.4(de)-6.4(ma)-426.9(ma)-6.4(nag)-5.3(eme)-6.4(nt)-5.4(.)-422.3(I)-5.2(n)-425.7(a)-.7(d)-5.3(d).5(i)-5.4(t).4(i)-5.4(o).5(n)-425.7(t)-5.4(o)-425.7(v).5(i)-5.4(s).7(it)-5.4(in)-5.3(g)-425.7(o).5(u)-5.3(t).4(p)-5.3(a)-.7(-)]TJ
0 -1.1116 TD
.0128 Tc
[(t)-5.7(i).1(e)-6.7(n).2(t)-264.9(c)-6.7(li)-5.7(ni)-5.7(cs,)-267.1(c)-6.7(on)-5.6(su)-5.6(lt)-5.7(ati)-5.7(o).2(n)-270.5(s).4(y)-5.6(s)]TJ
12.0608 0 TD
.0142 Tc
[(te)-5.3(ms)-268.9(such)-263.4(a)-5.3(s)-263.2(tele)-5.3(confere)-5.3(n)1.6(c)-5.3(e).4(s,)]TJ
-12.0608 -1.1116 TD
.017 Tc
[(vi)4.3(deo)4.4(c)-2.5(o)4.4(n)-1.4(f)4.4(e)-2.5(r)4.4(e)3.2(nces)4.6(,)-309(e)3.2(xchan)4.4(g)-1.4(es)-312.2(o)4.4(f)-306.6(ph)4.4(ot)4.3(og)4.4(rap)4.4(h)-1.4(i)4.3(c)-307.8(do)4.4(cu)4.4(men)4.4(t)-1.5(a-)]TJ
0 -1.1174 TD
.0176 Tc
[(ti)4.9(on)5(,)-314.1(m)3.8(ob)5(il)4.9(e)-313(p)-.8(h)5(o)-.8(n)5(e)-313(mess)5.2(ag)5(es,)-314.1(a)3.8(nd)-311.8(emai)4.9(ls)-311.6(or)-311.8(ot)4.9(her)-311.8(s)-.6(u)5(p)-.8(p)5(o)-.8(r)5(t)]TJ
0 -1.1116 TD
.0129 Tc
[(m)-6.7(obi)-5.6(le)-553.8(o)-5.5(r)-546.9(c)-6.6(o).3(m)-6.7(put)-5.6(er)-552.6(ap)-5.5(pl)-5.6(ic)-6.6(ati)-5.6(o).3(n)-5.5(s)-552.5(cou)-5.5(l).2(d)-552.6(h)-5.5(elp)-552.6(c)-6.6(ont)-5.6(ri)-5.6(bu)-5.5(te)]TJ
T*
[(t)-5.5(o)-310.6(t)-5.5(h).4(e)-317.6(i).3(m)-6.6(pro)-5.4(ve)-6.5(men)-5.4(t)-310.8(o)-5.4(f)-310.6(s)-5.2(el)-5.5(f-)-5.3(ca)-6.5(re)-317.6(for)-316.4(p)-5.4(a)-.8(ti)-5.5(en)-5.4(ts)-316.2(wi)-5.5(th)-316.4(ly)-5.4(mph)-5.4(e)-.8(-)]TJ
0 -1.1174 TD
.0148 Tc
[(dema)-551.9(a)-4.7(n)2.2(d)-550.7(d)-3.6(ecrea)-4.7(se)-551.9(the)-551.9(n)2.2(umbe)-4.7(r)-550.7(o)2.2(f)-550.7(p)-3.6(atients)-550.5(d)-3.6(eveloping)]TJ
0 -1.1116 TD
.0127 Tc
[(c)-6.8(e)-1.1(l)-5.8(l)0(ul)-5.8(it)-5.8(is)-5.5(.)]TJ
1.0137 -1.1116 TD
0 Tc
[(In)-295.9(this)-298.2(study,)-296.9(we)-292.2(targeted)-300.5(patients)-299.3(with)-293.5(lymphedema)-299.3(who)]TJ
-1.0137 -1.1116 TD
[(regularly)-432.9(visited)-429.5(lymphedema)-437.6(outpatient)-428.6(clinics.)-434.1(Most)-425.7(pa-)]TJ
0 -1.1174 TD
[(tients)-186.5(had)-188.8(secondary)-186(lymphedema)-189.9(\(98.2%\))-183.8(and)-183(ISL)-188.6(stage)-186.3(II)-180.7(or)]TJ
0 -1.1116 TD
[(late)-214.3(II)-215.2(\(total)-209.7(88.2%\).)-215(The)-213(proportion)-212.8(of)-209.5(patients)-218.7(with)-212.9(a)-209.6(history)]TJ
T*
[(of)-221(cellulitis)-221.3(was)-218.3(31.9%.)-219.7(Most)-218.4(patients)-218.7(in)-221.2(the)-217.7(study)-218.5(population)]TJ
0 -1.1174 TD
[(had)-200.3(normal)-193.4(weight)-199(\(60.1%\).)-198.8(These)-198.9(characteristics)-202.1(were)-197.6(not)-193.5(as)]TJ
0 -1.1116 TD
[(severe)-390(as)-389.1(those)-386.7(reported)-391.3(by)-388.1(other)-386.9(cited)-388.2(studies.)]TJ
7.3823 0 0 6.5614 252.7936 170.5323 Tm
(6)Tj
9.843 0 0 9.843 260.3338 166.1669 Tm
(However,)Tj
-20.3778 -1.1116 TD
[(lymphatic)-324.9(abnormalities)-330.4(cause)-319.8(changes)-327.8(in)-319.1(the)-321.4(inammatory)]TJ
0 -1.1174 TD
[(status)-220.7(and)-211.8(increase)-220.7(the)-217.7(risk)-217.4(of)-209.5(devel)-8(oping)-213(cellulitis)-215.5(regardless)]TJ
0 -1.1116 TD
[(of)-566.6(lymphedema)-570(severity.)]TJ
7.3823 0 0 6.5614 163.8992 137.6504 Tm
(1618)Tj
9.843 0 0 9.843 187.937 133.285 Tm
[(Therefore,)-570.9(the)-569(health)-567.9(care)]TJ
-13.0227 -1.1116 TD
[(system)-210.3(should)-202.4(be)-210.7(expanded)-202.4(to)-209.7(reach)-204.8(patients)-207.2(who)-205.8(cannot)-210.7(visit)]TJ
0 -1.1174 TD
[(the)-327.1(outpatient)-330.6(department)-327(or)-330.5(who)-321(have)-329.3(lymphedema)-328.1(of)-324.7(any)]TJ
0 -1.1116 TD
(severity.)Tj
1.0137 -1.1116 TD
[(This)-523.9(study)-518.1(had)-517.1(three)-526.3(limitations.)-519.6(First,)-521.4(data)-519.5(on)-520.6(actual)]TJ
-1.0137 -1.1116 TD
[(physical)-351(distance)-352.2(and)-344.3(communication)-354.7(details)-350(of)-347.8(the)-344.4(regular)]TJ
0 -1.1174 TD
[(visits)-404(to)-399.7(the)-402(outpatient)-405.5(clinics)-401.9(were)-405(not)-400.9(collected.)-410.1(Second,)]TJ
0 -1.1116 TD
[(cellulitis)-307.7(information)-297.1(included)-305.1(only)-298.3(the)-298.3(presence)-307(or)-295.9(absence)]TJ
25.5097 55.6676 TD
[(of)-319(history)-324.5(of)-319(cellulitis.)-328.4(The)-322.5(frequency)-324.4(of)-324.7(recurring)-323.3(cellulitis)]TJ
0 -1.1116 TD
[(might)-260.4(be)-262.5(related)-264.9(to)-261.5(a)-261.4(high)-263.7(risk)-263.5(of)-261.4(recurrent)-261.1(cellulitis)-267.3(and)-263.7(less)]TJ
T*
[(consultation)-217.5(environment)-217.5(to)-209.7(professionals.)-221.3(Finally,)-214.1(data)-214.2(were)]TJ
0 -1.1174 TD
[(only)-275.2(collected)-285.7(from)-276.3(two)-280.8(facilities)-279.9(located)-282.2(in)-278.8(rural)-277.4(areas.)-282.9(The)]TJ
0 -1.1116 TD
[(social)-268.2(background)-266.7(may)-270.6(differ)-267(from)-270.5(that)-265(in)-267.3(an)-268.3(urban)-265.8(area)-272.8(and)]TJ
T*
[(other)-191.1(countries;)-197.8(however,)-192.9(we)-194.3(could)-191.1(refer)-192(to)-192.4(other)-191.1(publications)]TJ
0 -1.1174 TD
[(to)-278.8(consider)-281.7(the)-281.1(clinical)-289.3(implementations.)]TJ
1.0137 -1.1116 TD
[(Further)-204.6(investigations)-208.1(are)-207.2(required)-207(to)-203.9(consid)-7.7(er)-204.9(feasible)-208.2(and)]TJ
-1.0137 -1.1116 TD
[(sustainable)-499.4(approaches)-505(for)-498.6(the)-499.9(development)-500.9(of)-497.5(telehealth)]TJ
0 -1.1174 TD
[(systems)-303.4(that)-305.3(will)-305.2(support)-307.1(the)-304.1(self-care)-308.1(of)-301.7(patients)-305.1(with)-305(lym-)]TJ
0 -1.1116 TD
[(phedema)-283.1(for)-279.7(the)-281.1(prevention)-284.3(of)-278.6(recurrent)-284.1(cellulitis.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 466.1857 Tm
(Conclusions)Tj
/F5 1 Tf
9.843 0 0 9.843 320.8251 449.7448 Tm
[(A)-307.2(history)-307.2(of)-307.4(cellulitis)-313.4(in)-307.6(patients)-310.8(with)-305(lymphedema)-316.6(is)-307.4(as-)]TJ
-1.0137 -1.1174 TD
[(sociated)-381(with)-374.2(limited)-379.2(access)-379.5(to)-376.7(specialists.)-381.8(To)-377.8(prevent)-378.8(cel-)]TJ
0 -1.1116 TD
[(lulitis)-336.5(in)-330.6(this)-338.5(patient)-338.7(population,)-332.8(services)-340.3(such)-333.7(as)-337.2(telehealth)]TJ
T*
[(systems)-303.4(can)-299.4(be)-302.9(applied)-304(to)-296.1(impro)-6.8(ve)-297.1(communication)-308.7(between)]TJ
T*
[(specialists)-274.7(and)-269.4(patients)-270.5(and)-269.4(decre)-9(ase)-270.4(episodes)-270.1(of)-272.9(cellulitis)-273.1(in)]TJ
0 -1.1174 TD
[(patients)-282(with)-282(lymphedema.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 373.0392 Tm
(Acknowledgments)Tj
/F5 1 Tf
9.843 0 0 9.843 320.8251 356.5983 Tm
[(We)-403(appreciate)-408.7(all)-402.1(the)-402(board)-404.1(members:)-410.9(Professor)-402.1(Emiko)]TJ
-1.0137 -1.1174 TD
[(Kimura,)-456.9(Dr.)-455.7(Noriko)-462.6(Kobayashi,)-460(Professor)-459.7(Ayako)-456.8(Okutsu,)]TJ
0 -1.1116 TD
[(Professor)-569.1(Toyoko)-572.3(Yoshizawa,)-571.5(Professor)-569.1(Hiromi)-573.4(Sakuda,)]TJ
T*
[(Professor)-574.9(Mariko)-573.2(Masujima,)-575.5(Dr.)-570.9(Ayumi)-572.2(Naito,)-575.7(and)-568.9(Dr.)]TJ
0 -1.1174 TD
[(Akitatsu)-218.4(Hayashi)-224(and)-217.6(auditors;)-224.4(Ms.)-219.4(Yoko)-218.4(Ayai)-219.7(and)-223.3(Professor)]TJ
0 -1.1116 TD
[(Shizuko)-365.9(Murayama)-365.7(and)-367.3(secretaries;)-370.3(Dr.)-363.6(Terumi)-367.4(Ueda,)-368.1(Ms.)]TJ
T*
[(Sayumi)-204.8(Tsuchiya,)-205.8(and)-200.3(Dr.)-208.1(Maho)-202.3(Aoyama)-206.9(of)-203.8(the)-206.2(International)]TJ
0 -1.1174 TD
[(Lymphoedema)-284.2(Framework)-284.8(Japan.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 251.0929 Tm
[(Authors)-334(Contributions)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 234.6519 Tm
[(C.J.M.)-309.1(and)-309.7(S.M.)-315.1(conceived)-314.2(and)-309.7(designed)-316.3(the)-309.9(LIMPRINT)]TJ
-1.0137 -1.1116 TD
[(study,)-291.1(and)-298.2(H.S.)-292(coordinated)-298.1(all)-298.5(procedures)-296.5(in)-296.1(Japan.)-293.3(J.S.)-296.7(ar-)]TJ
0 -1.1174 TD
[(ranged)-348.7(this)-350.1(investigation)-356.9(among)-347.7(the)-350.2(multiple)-351.5(facilities,)-358.2(and)]TJ
0 -1.1116 TD
[(M.D.)-189.4(and)-188.8(A.S.)-188.3(performed)-186.2(the)-188.9(investigation.)-193.3(P.J.F)-188.2(managed)-191(all)]TJ
T*
[(the)-390.5(data)-392.8(and)-390.4(then)-391.6(G.N.)-391(and)-390.4(M.D.)-391(performed)-393.5(the)-390.5(statistical)]TJ
T*
[(analysis.)-221.8(H.K.)-223.9(and)-223.3(M.K.)-224(interpreted)-229(the)-223.5(results)-221.8(based)-226.5(on)-221.1(their)]TJ
0 -1.1174 TD
[(specialties.)-256.5(M.D.)-252.8(drafted)-252(the)-252.3(rst)-251.8(article.)-256.9(G.N.,)-250.4(H.S.,)-255.1(and)-252.1(J.S.)]TJ
0 -1.1116 TD
[(reviewed)-335.8(the)-338.7(article.)-337.5(All)-332.7(authors)-337.1(revised)-338.2(the)-338.7(article)-334.1(and)-338.5(ap-)]TJ
T*
[(proved)-278.4(the)-281.1(nal)-282(version)-285.2(of)-278.6(the)-281.1(article.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 118.2047 Tm
[(Data)-329.9(Sharing)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 101.7638 Tm
[(The)-276.4(data)-283.3(are)-282.1(not)-279.9(publicly)-286.8(available)-285.7(or)-278.6(accessible.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 73.0205 Tm
[(Author)-332.4(Disclosure)-336.7(Statement)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 56.5795 Tm
[(No)-279.5(competing)-284.4(nancial)-283.1(interests)-282.9(exist.)]TJ
ET
59.754 719.49 490.167 .22668 re
f
59.754 652.138 490.167 .22681 re
f
59.754 700.781 490.167 .22681 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 145.9275 725.1588 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(3.)Tj
/F9 1 Tf
1.2496 0 TD
[(Multivariable)-331.4(Logistic)-337.2(Regression)-334(for)-332.2(History)-335.6(of)-337(Cellulitis)]TJ
/F6 1 Tf
-13.0028 -1.8427 TD
[(Variables)-11424.7(Crude)-335.2(odds)-337.8(ratio)-1807.6(95%)-332.2(CI)]TJ
/F5 1 Tf
29.979 0 TD
(p)Tj
/F6 1 Tf
2.7699 0 TD
[(Adjusted)-332.9(odds)-332(ratio)-1813.3(95%)-332.2(CI)]TJ
/F5 1 Tf
15.669 0 TD
(p)Tj
-48.4178 -1.9003 TD
[(Age,)-336.6(years)-13580(0.99)-4020(0.971.01)-1390(0.609)-4522(0.96)-4521(0.981.01)-1395.7(0.462)]TJ
0 -1.0077 TD
[(Edema)-337.9(duration,)-335.3(years)-8777.4(3.12)-4020(1.337.35)-1390(0.009)-4522(4.10)-4521(1.5311.0)-1395.7(0.005)]TJ
0 -1.0135 TD
[(ISL)-338(classication)-10872.6(0.80)-4020(0.341.87)-1390(0.607)-4522(1.51)-4521(0.554.17)-1395.7(0.428)]TJ
T*
[(Access)-338.2(to)-336.2(lymphedema)-332.6(specialists)-4022.5(0.26)-4020(0.110.62)-1390(0.002)-4522(0.28)-4521(0.110.74)-1395.7(0.009)]TJ
8.7511 0 0 8.7511 67.748 640.2896 Tm
[(CI,)-331.7(condence)-337.4(interval;)-328.7(ISL,)-337(International)-330.3(Society)-334.8(of)-333.1(Lymphology.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(UNREASONABLE)-344.6(DISTANCE)-332.4(WITH)-335.9(LYMPHEDEMA)-337.8(PATIENTS)-336.7(AND)-337.2(SPECIALISTS)-336(PRONE)-339.6(TO)-331.2(CELLULITIS)-2421.2(445)]TJ
ET
endstream
endobj
43 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
8.9663 0 0 8.9663 62.022 725.7825 Tm
0 0 0 rg
0 Tc
0 Tw
[(Funding)-334.6(Information)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 709.3416 Tm
[(The)-310.9(International)-312(Lymphoedema)-318.8(Framework,)-311.3(Japan,)-310.6(par-)]TJ
-1.0137 -1.1116 TD
[(tially)-284.8(supported)-281.7(this)-280.9(study.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 676.4597 Tm
(References)Tj
/F5 1 Tf
9.2951 0 0 9.2951 66.6708 660.4155 Tm
[(1.)-500.4(Chlebicki)-439.7(MP,)-435.6(Oh)-441(CC.)-436.9(Recurrent)-443.6(cellulitis:)-438.1(Risk)-436.9(factors,)]TJ
1.2503 -1.1283 TD
[(etiology,)-369.7(pathogenesis)-371.3(and)-370.6(treatment.)-374(Curr)-369.9(Infect)-367.1(Dis)-372.6(Rep)]TJ
0 -1.1223 TD
[(2014;)-335.6(16:422.)]TJ
-1.2503 -1.1284 TD
[(2.)-500.4(Cranendonk)-285.3(DR,)-281.2(Lavrijsen)-280.3(APM,)-284.8(Prins)-278.9(JM,)-285.4(Wiersinga)-282.7(WJ.)]TJ
1.2503 -1.1223 TD
[(Cellulitis:)-341.1(Current)-337.3(insights)-339.2(into)-334.9(pathophysiology)-339.2(and)-334(clini-)]TJ
0 -1.1284 TD
[(cal)-337.6(management.)-334.1(Neth)-335.1(J)-334.7(Med)-333.3(2017;)-335.6(75:366378.)]TJ
-1.2503 -1.1223 TD
[(3.)-500.4(Teasdale)-421(EJ,)-416.1(Lalonde)-419.4(A,)-416.5(Muller)-420.3(I,)-417.3(et)-412.6(al.)-418.7(Patients)-421(under-)]TJ
1.2503 -1.1284 TD
[(standing)-351(of)-350.3(cellulitis)-353.2(and)-346.2(views)-352.7(about)-352(how)-349.7(best)-351(to)-347.4(prevent)]TJ
0 -1.1223 TD
[(recurrent)-453.4(episodes:)-452(Mixed-methods)-454.7(study)-450.6(in)-451(primary)-454.1(and)]TJ
0 -1.1284 TD
[(secondary)-338.6(care.)-332.8(Br)-336.7(J)-334.7(Dermatol)-335.2(2019;)-335.6(180:810820.)]TJ
-1.2503 -1.1223 TD
[(4.)-500.4(Al-Niaimi)-435.2(F,)-436.2(Cox)-438.3(N.)-434.8(Cellulitis)-433.1(and)-437.7(lymphoedema:)-439.3(A)-434.8(vi-)]TJ
1.2503 -1.1284 TD
[(cious)-332.8(cycle.)-336.1(J)-334.7(Lymphoedema)-338.5(2009;)-335.6(4:342.)]TJ
-1.2503 -1.1223 TD
[(5.)-500.4(Dai)-335(M,)-341(Nakagami)-337.6(G,)-337.3(Sugama)-335(J,)-340.9(et)-333.3(al.)-339.4(The)-335.9(prevalence)-341.4(and)]TJ
1.2503 -1.1284 TD
[(functional)-467.9(impact)-471.2(of)-472.2(chronic)-468.6(edema)-470.4(and)-468.2(lymphedema)-476.2(in)]TJ
T*
[(Japan:)-434.8(Limprint)-430.2(study.)-426.3(Lymphat)-433.1(Res)-429.4(Biol)-431.2(2019;)-433.2(17:195)]TJ
0 -1.1223 TD
(201.)Tj
-1.2503 -1.1284 TD
[(6.)-500.4(M)12.8(o)0(f)15.7(f)15.8(at)20.5(t)-402.1(C)13.4(J,)-389.7(F)15.3(r)0(a)17.6(n)0(k)24.1(s)-401.8(P)15.3(J)0(,)-389.7(D)0(o)22.5(h)0(e)19.9(r)0(t)22.4(y)-396.6(DC)17.8(,)-396.5(e)0(t)-388.2(a)14(l.)-390(Ly)22.2(m)12.5(p)0(h)18(o)0(e)19.9(d)0(e)26(m)0(a)20.3(:)]TJ
1.2503 -1.1223 TD
[(An)-276.3(un)24.1(de)19.9(re)17.6(s)12.9(t)0(i)19.2(m)12.5(at)20.5(ed)-279(he)19.9(a)14(l)0(t)19.2(h)-286.8(pr)21.8(ob)18(l)12.6(e)0(m)20.3(.)-286.7(QJ)23.4(M)-286.1(2)0(0)18(0)0(3)24.1(;)-286.2(96)18(:)12.6(7)0(3)18(1)0()24.1(7)0(3)24.1(8)0(.)]TJ
-1.2503 -1.1284 TD
[(7.)-500.4(Moffatt)-526.4(C,)-523.4(Franks)-527.8(P,)-521.5(Keeley)-526.8(V,)-526.3(Murray)-527.4(S,)-521.5(Mercier)-529.3(G,)]TJ
1.2503 -1.1223 TD
[(Quere)-427.8(I.)-429.5(The)-433.5(development)-427.4(and)-431.6(validation)-428.4(of)-429.6(the)-424.9(limprint)]TJ
0 -1.1284 TD
[(methodology.)-333.7(Lymphat)-335.5(Res)-337.9(Biol)-333.6(2019;)-329.5(17:127134.)]TJ
-1.2503 -1.1223 TD
[(8.)-500.4(International)-419.4(Society)-413.7(of)-411.2(Lymphology.)-411.1(Document)-418.8(C,)-413.6(Con-)]TJ
1.2503 -1.1284 TD
[(gress)-261.6(XVII,)-264.6(et)-266.2(al.)-260.2(The)-268.8(diagnosis)-264.9(and)-260.8(treatment)-264.2(of)-264.9(peripheral)]TJ
0 -1.1223 TD
[(lymphedema:)-549(2016)-537.3(consensus)-549.9(document)-545.3(of)-539.3(the)-546.9(Interna-)]TJ
0 -1.1284 TD
[(tional)-314.4(Society)-310(of)-313.7(Lymphology.)-307.4(Acta)-315(Angiol)-312.4(2017;)-311.2(49:170)]TJ
0 -1.1223 TD
(184.)Tj
-1.2503 -1.1284 TD
[(9.)-500.4(Mihara)-339.6(M,)-341(Hara)-342.2(H,)-337.3(Tsubaki)-341.1(H,)-337.3(et)-339.4(al.)-345.5(Combined)-338.5(conserva-)]TJ
1.2503 -1.1223 TD
[(tive)-247.6(treatment)-252(and)-248.6(lymphatic)-251.5(venous)-248.2(anastomosis)-255.8(for)-249(severe)]TJ
0 -1.1284 TD
[(lower)-264.4(limb)-255.2(lymphedema)-268.8(with)-257.2(recurrent)-264.3(cellulitis.)-261.8(Ann)-264.3(Vasc)]TJ
0 -1.1223 TD
[(Surg)-335.1(2015;)-329.5(29:1318.e11e1318.e15.)]TJ
-1.7505 -1.1284 TD
[(10.)-500.5(Lasinski)-431.3(BB,)-436.9(Thrift)-433.2(KM,)-428.1(Squire)-436.7(DC,)-433.7(et)-430.9(al.)-430.9(A)-434.8(systematic)]TJ
1.7505 -1.1223 TD
[(review)-360.3(of)-356.4(the)-363.9(evidence)-359(for)-358.8(complete)-359.9(decongestive)-364.2(therapy)]TJ
0 -1.1284 TD
[(in)-304.7(the)-309(treatment)-306.9(of)-307.6(lymphedema)-311.5(from)-303.6(2004)-305.5(to)-310.8(2011.)-305.6(PM)-301.3(R)]TJ
0 -1.1223 TD
[(2012;)-335.6(4:580601.)]TJ
-1.7505 -1.1284 TD
[(11.)-500.5(M)12.8(o)0(f)15.7(f)15.8(at)20.5(t)-969.3(C)0(.)]TJ
/F6 1 Tf
7.5935 0 TD
[(Be)18(s)12.9(t)-969.3(Pr)17(ac)26(ti)19.2(ce)-960.2(fo)18.6(r)-969(t)12.6(he)-962.1(Ma)21.6(na)24.1(ge)19.9(me)18.3(nt)-957.3(of)]TJ
-5.8431 -1.1223 TD
[(Ly)23.1(mp)16.4(ho)24.1(ed)19.9(em)18.3(a)24.9(In)15.7(t)12.6(e)0(r)20.8(n)0(a)24.1(t)0(i)19.2(o)0(n)18(a)0(l)-201(C)0(o)19.3(n)0(s)18.9(e)14(ns)18.9(us)]TJ
/F5 1 Tf
16.1447 0 TD
[(.)-213.5(\()0(C)23.1(h)0(r)21.8(i)0(s)19.5(t)0(i)19.2(n)0(e)-205.8(M)12.8(of)21.8(fa)17.6(t)12.6(t)0(,)]TJ
10.8627 46.3542 TD
[(De)18.3(br)21.8(aD)18.3(oh)24.1(er)17.6(t)12.6(y)0(,)-445.5(P)0(h)21.2(i)0(l)-450.5(M)12.8(or)21.8(ga)19.9(n,)-445.5(M)12.8(a)0(c)15.7(G)0(r)20.2(e)14(go)18(r)-453.8(L)0(,)-447.3(e)0(d)19.9(.)0(\))21.9(.)-457.5(Lo)22.2(nd)24.1(on)18(:)]TJ
0 -1.1223 TD
[(Me)20.6(di)18.6(ca)21.8(l)-499.7(E)0(d)22.2(u)0(c)19.9(a)0(t)20.5(i)12.6(on)-488.2(Pa)23.1(rt)16.3(ne)26(rs)16.6(hi)24.7(p)-500.3(\()-69.5(ME)16.9(P)15.3(\))-496.5(Lt)16.7(d;)-481.6(20)18(06)24.1(.)-500.2(h)0(t)24.7(t)0(p)18.6(s)12.9(:/)19.2(/)]TJ
0 -1.1284 TD
[(ww)14.9(w)22.7(.)0(l)24.8(y)0(m)18.4(p)0(h)24.1(o)18.2(.o)24.2(rg)21.8(/w)17(p-)21.8(co)19.9(nt)18.6(e)14(n)0(t)18.6(/)12.6(up)18(l)12.6(o)0(a)19.9(d)0(s)25(/)0(2)18.6(0)0(1)24.1(6)0(/)18.6(0)0(3)24.1(/)0(B)19.9(e)0(s)20.8(t)0(_)18.6(p)0(r)21.8(a)0(c)15.7(t)12.6(i)12.6(c)0(e)]TJ
0 -1.1223 TD
[(.p)18.1(df)21.8(.)]TJ
-1.7505 -1.1283 TD
[(12.)-500.5(Sivan)-293.9(M,)-286.1(Halpin)-292.2(S,)-289.8(Hollingworth)-291.6(L,)-288.8(Snook)-290.3(N,)-288.5(Hickman)-290.6(K,)]TJ
1.7505 -1.1223 TD
[(Clifton)-604.1(IJ.)-599.5(Development)-599.8(of)-600.3(an)-596.1(integrated)-600.2(rehabilitation)]TJ
0 -1.1284 TD
[(pathway)-321.5(for)-316.1(individuals)-319.8(recovering)-317(from)-321.9(COVID-19)-320.3(in)-316.9(the)]TJ
0 -1.1223 TD
[(community.)-339.1(J)-334.7(Rehabil)-336.3(Med)-333.3(2020;)-329.5(52:jrm00089.)]TJ
-1.7505 -1.1284 TD
[(13.)-500.5(Douglass)-279.1(J,)-279.9(Graves)-274.6(P,)-277.6(Gordon)-273.1(S.)-277.6(Self-care)-283.6(for)-273.4(management)]TJ
1.7505 -1.1223 TD
[(of)-575.9(secondary)-582.6(lymphedema:)-579.4(A)-575(systematic)-577.4(review.)-579.9(PLoS)]TJ
0 -1.1284 TD
[(Negl)-335.1(Trop)-334.1(Dis)-336(2016;)-335.6(10:e0004740.)]TJ
-1.7505 -1.1223 TD
[(14.)-500.5(Riegiel)-280.9(B,)-279.5(Jaarsma)-282.1(T,)-282.7(Stromberg)-280.4(A.)-276.3(A)-282.3(middle-range)-279.7(theory)]TJ
1.7505 -1.1284 TD
[(of)-338.1(self-care)-334.7(of)-338.1(chronic)-334.4(illness.)-337.3(ANS)-329.7(2012;)-335.6(35:194204.)]TJ
-1.7505 -1.1284 TD
[(15.)-500.5(Negarandeh)-424.7(R,)-413.7(Zolfaghari)-423.9(M,)-414.2(Bashi)-416.9(N,)-416.5(Kiarsi)-421.7(M.)-414.2(Evalu-)]TJ
1.7505 -1.1223 TD
[(ating)-577.1(the)-571.3(effect)-578.7(of)-569.8(monitoring)-575(through)-570(telephone)-580(\(tele-)]TJ
0 -1.1284 TD
[(monitoring\))-351.7(on)-341.8(self-care)-353(behaviors)-352.1(and)-346.2(readmission)-350.5(of)-344.2(pa-)]TJ
0 -1.1223 TD
[(tients)-368.4(with)-373.1(heart)-364.6(failure)-372.8(after)-367(discharge.)-368.6(Appl)-367.5(Clin)-370.2(Inform)]TJ
0 -1.1284 TD
[(2019;)-335.6(10:261268.)]TJ
-1.7505 -1.1223 TD
[(16.)-500.5(Brayton)-335(KM,)-324.5(Hirsch)-330.8(AT,)-327.1(OBrien)-332.8(PJ,)-325.6(Cheville)-335.9(A,)-325.1(Karaca-)]TJ
1.7505 -1.1284 TD
[(Mandic)-630.1(P,)-631.3(Rockson)-631.2(SG.)-627(Lymphedema)-631.1(prevalence)-634.2(and)]TJ
0 -1.1223 TD
[(treatment)-471.5(benets)-468.3(in)-463.2(cancer:)-464.8(Impact)-468(of)-466.1(a)-461.8(therapeutic)-470.4(in-)]TJ
0 -1.1284 TD
[(tervention)-345.9(on)-341.8(health)-343.6(outcomes)-349.3(and)-340.1(costs.)-344.2(PLoS)-343.7(One)-341.7(2014;)]TJ
0 -1.1223 TD
(9:115.)Tj
-1.7505 -1.1284 TD
[(17.)-500.5(Keast)-582.6(DH,)-576.8(Moffatt)-581.3(C,)-578.3(Janmohammad)-579.3(A.)-581.2(Lymphedema)]TJ
1.7505 -1.1223 TD
[(impact)-428.6(and)-425.5(prevalence)-432.9(international)-428.7(study:)-425.8(The)-421.3(Canadian)]TJ
0 -1.1284 TD
[(data.)-337.9(Lymphat)-335.5(Res)-331.8(Biol)-339.7(2019;)-329.5(17:178186.)]TJ
-1.7505 -1.1223 TD
[(18.)-500.5(Soo)-375.4(JK,)-379.2(Bicanic)-377.1(TA,)-375.9(Heenan)-374.9(S,)-375.2(Mortimer)-379.7(PS.)-372.1(Lymphatic)]TJ
1.7505 -1.1284 TD
[(abnormalities)-568.2(demonstrated)-563.2(by)-555.3(lymphoscintigraphy)-564.8(after)]TJ
0 -1.1223 TD
[(lower)-313.2(limb)-304(cellulitis.)-310.6(Br)-306.2(J)-304.2(Dermatol)-310.8(2008;)-305.1(158:13501353.)]TJ
9.843 0 0 9.843 441.014 409.3228 Tm
[(Address)-337.6(correspondence)-337.8(to:)]TJ
/F6 1 Tf
1.0655 -1.1116 TD
[(Junko)-336.1(Sugama,)-333.5(PhD,)-337.1(RN)]TJ
-8.2421 -1.1116 TD
[(Research)-335.7(Center)-338.2(for)-337.3(Implementation)-336.8(Nursing)]TJ
11.4273 -1.1174 TD
[(Science)-340.8(Initiative)]TJ
-3.6574 -1.1116 TD
[(School)-336.2(of)-336.4(Health)-331.4(Scien)-8(ces)]TJ
.6681 -1.1116 TD
[(Fujita)-336.5(Health)-337.2(University)]TJ
-5.489 -1.1116 TD
[(1-98,)-330.4(Denga)-7.5(kugakubo,)-331.4(Kutsukake-cho)]TJ
12.1242 -1.1174 TD
(Toyoake)Tj
-2.8971 -1.1116 TD
[(Aichi)-336.4(470-1192)]TJ
3.8475 -1.1116 TD
(Japan)Tj
-13.0976 -1.6703 TD
(E-mail:)Tj
/F5 1 Tf
3.3982 0 TD
(junko.sugama@fujita-hu.ac.jp)Tj
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(446)Tj
49.3883 0 TD
[(DAI)-331.6(ET)-338.7(AL.)]TJ
ET
endstream
endobj
49 0 obj
<>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
51 0 obj
<>stream
hބTPT9lȹ8DKP+ cq@T)0@4>hMMժhˤ4/NĦI&νsf}FҹHؘ9Q6OiTIFÜMݪ=%5ҚeoS^ISB_Ny3uEIr,v%:'j˵LytER&bu%+ߒfR2Iɳ̖l-SWb2ry\T1嘃6%C7g3L}79HIS%E
YH/$"HH\Ili4j..ZmvRu9K'$>:f}S#^7\R"<:.ud³`!˰I%= ڱ6\IcZp&78v$KSa.u1d~vCb#C
.nB P0w9uυϰ^!G6sҘaXvFs^e8%ꂉM+ .drfߌΜp%u|
3nm?7S^?WwXp?7Í }z# c;AǟM6aXp xaf~#mG_a7l@Q\U{F٭^:w{~9<߱ҵ-yy/f
o7^RVRR9Jkڪx/|D'_gb(OOA,pUjboxj5߳Vo ocChsNݡ5e.[;ߣ@lke4O<dt
`Iw^`"nP`TE/SQ962[6s[@ÆvqØ`<&aHR C}80X]n<+ia$Eq@dž_^؊^syN${\r撘l2hp՝B?-MZwОz|\|Mea\ RWɍRin9jkyuRQ\\Qf'/[BH$-\D *rWW i߈pCRFWοs(ܹY~[*hv&Q^Pe;&ޘEhO8AW"\
)Т*c6*7Ӟ=E1@~)#s^/'Op4)<GSxB|;X)=%.u\bAqVia}T1xFQFsg`TpGrg^ƨBUȽġm2l8{ҩOfW'd[Iۡ .ךz:iܱE\|I
WU7KbvxFW;/Zx`rԤO,a|ǧbJ᳐/zA|C|Q}$[ *?
endstream
endobj
53 0 obj
<>stream
8;Z\7#nFiq%*SZ8aEKPAX9?U5+LG656)X!qUs>9<&'Dq\r1c=R;H-bJ
Jji,+NeBb+Zf'KJIoh1MmO"Iq5"*Wo:u]EJ'3(:_O:3o@H<][`"oAWMi
_LkD72B"o)2?+DK&kSF4fPZn-aj%+,;?_>f82PQJY_MW,EFW,F4;VH9p.1^KabVL+
l(j'.(K/Uh&81M]@+4M.pS/'0o&W-,7B\>L]V[gZW7AC,/r+MimKiL^+u^14a,NU>
W]F%,g8+"sf*"0U90HDK29;$_CNQIIKe,m93jo?+`$%G,in4,qJ?0,!%U+j9p3me#iBR!+N]8q>~>
endstream
endobj
21 0 obj
<>stream
8;Z\7$')kV%,Cl4d,.t4Ft4KWN:"Pt6,J3tdU]MV+dd[nU4.L#2FH@CA+*Hj/)V#n
S&=[C2)GHQ+dSZ_-ERGkL%d[>Hs_67m3OC^IoWc!(hN4V4@YMuiK9+iStQ.4BP\!*%t&=fLV1:G35'_&fqLL
P$156/%Smt@U'e_g4TH`4^otj^,Z_!+r\d]1oDm*YfCfjm.?V>GM@:t4FJ!<]-M3FMJSG%K]=:n4mPNKVXcda*`4`@FfBN"^h_cR=
h:R!qP`-UQEt!a(DKR_T;e*P2f@?IZ0WBP=M+<;sD^VgV\<*Cg/+U2l^'@,k:u*0-
[p$W',Nf]t)bkeIZg2f87CPe9~>
endstream
endobj
32 0 obj
<>stream
8;Z\7dC-q8#kS(Gd,3Ne]5&--!>N#0o!"[ZL*Y4$f)!
endstream
endobj
40 0 obj
<>stream
8;Z\7>7uQ2%.*pGaE9P/(;Z*Q-37a?mRJ?ipEcaijadLe$8PXohi?UNm2cIqn4_BH
D_pFm1t\&l3)dlP+BjOn*T$"\%\H6aS'[4>__YYF>]F,=@/:<+KgRUb0+e^aB\c#2
-XLPqPE,F\jN>EPN9'u#fGD1I^Lgl3b4oM6NtKD,`R(=UMggt52F0qQ+>=pc-$sF!%#L5
0^#HWn\-Kf@tl@G^@k%8/)@Xh1=t,*S2:E2)EqO.f.DWs(V;)C)9HJhn+`(7\?GP=
N;O"h<_+En),n%Q?S4'(`W
endstream
endobj
44 0 obj
<>stream
8;Z\65nX8C#kS'Rhp.Q5/uu\n6jR
b'k8F6!e3@QptgdI3k[Wk7k2AXD?)]jN#e\p>"/D*(l8_:ZIW3U-n4q2CMfi<+)Ok
GmV@u-=gf7%Ht^83F0@2Ys`WkW\o2bCicb\P]@Nhl+ac$"5nc7pn9rh@3diTp%.%+
g(Y@u'nj#>)Ys<('B?soZV^C]i_%2Pm]oZVc*jU[H)6f%f_'3s;K6&D>k[rXOCT3.
_I\`+.jXDN(<_V0$ZNqAkZ$
endstream
endobj
57 0 obj
<>
endobj
58 0 obj
<>stream
H]o04]WX5v1¥)d*D]&$t~zI\3l4[LFFcbϔX
GV:&W5EUǜkLey|ؠz{fB&
ď
1Vqsu;XK*1Ŕ
TnivES$zą=pe;ע٦cw̘aC:ĪUdMJ; 5 ƌ%mB\Č]ݧOUЕk܃yV1܆"b+
^b&M\A,(~{5uцMV1.A3& fRP=h0 1iOp8侨#TH½18Jyg`${F<FQu59fؠC0HN/ +`bM +xaH7Q]婸\]b^D"cu߿L0>9*I-L&GEP(uB:wEWTm7 B]`c8nk8ñ c'AɅ5MdѠ%z[M/?K&1==|c -_:"9AC]cwV!}#n &LawV݁VkhZBvFLT ]+t3>#
:0\x\qNch^q7[7ih/innސf ̬
endstream
endobj
59 0 obj
<>stream
H\Uˮ6+$XIQ,"@(,Tʢ*Rw;ʾ73g?Vy~x<lVU)˵>&y[qdδxln,
wQpd.接~L
+eE)yWYZcM̊MEA5YӉf/.!ڲ^@p_eDj"AYkVCEV 3#;Y)ս $,g ߈)?)3xRYޘBv:?
=˓a_#?AS329-)}6e[H5)Yޱntua(MuZ3_eį0]G
%<Z4H